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Abstract 
Methylation of CpG dinucleotides is the major epigenetic modification of mammalian 
DNA which results in the remodelling of transcriptionally active euchromatin to 
transcriptionally inactive heterochromatin.  Recognition of methylated CpG by 
methylated DNA binding proteins, the MBD family, the Kaiso zinc finger family and the 
SRA domain proteins results in deacetylation and methylation of histone side chains 
through the recruitment of HDAC and HMT enzymes.  Methylation of DNA is a 
heritable process ensuring Methylation dependant transcriptional repression is passed 
from mother to daughter cell during replication.  Some of the proteins involved in this 
chromatin remodelling, MBD1, DNMT1, MLL, and CFP1 contain CXXC domains.  
hMBD1 contains 2 or 3 CXXC domains depending on the splice variant, with only the 
third CXXC domain shown to bind CpG dinucleotides.     
 
This thesis describes the work done to elucidate the structure of hMBD1 CXXC1 and to 
investigate hMBD1 CXXC12 di-domain by NMR spectroscopy and biochemical 
characterisation.  The hMBD1 CXXC1 & CXXC12 domains were successfully over 
expressed in E. coli and purified.  Unlabelled and uniformly 15N labelled proteins were 
produced for nuclear magnetic resonance (NMR) studies.  Assignment of NMR spectra 
was carried out and constraints generated enabling structure determination of hMBD1 
CXXC1 and to investigate the relationship between CXXC1 and CXXC2 of hMBD1.  
 
The solution structure of hMBD1 CXXC1 determined here was compared to the 
previously determined solution structure of hMLL CXXC in order to investigate their 
differences in DNA binding.  NOE data from hMBD1 CXXC1 and CXXC12 are 
compared in order to investigate the domain structure of CXXC12.  DNA titration of 
hMBD1 CXXC1 showed no significant interaction with a single CpG oligo while the 
loop region of hMBD1 CXXC1 differs significant in both structure and surface charge 
suggesting the loop region to be important for DNA binding.  The recorded NOE data of 
hMBD CXXC12 suggests the two CXXC domains form a globular rather than a linear 
structure      
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1.1 Epigenetics 
Epigenetics is the study of heritable changes in gene function that occur without a 
change in the sequence of nuclear DNA.  This form of inheritance allows the 
transmission of information from mother to daughter cell without the information being 
encoded in the nucleotide sequence of the gene, for example when a liver cell divides, 
the daughter cells do not start to express proteins specific to muscle cells.  Methylation 
of a CpG dinucleotide at cytosine C5 (mCpG) is a major epigenetic gene silencing 
modification in vertebrate genomes.  This modification recruits proteins which 
specifically recognise this motif.  These methylated DNA binding proteins then recruit 
enzymes which chemically and physically alter chromatin, which induces transcriptional 
repression.  Although most CpG motifs are methylated it should be noted that short 
(500-2000bp) CG-rich regions, known as CpG islands, found within 60% of human gene 
promoters remain non-methylated (Bird, A. 2002).   While this is true for normal cells, 
de novo methylation of CpG islands occurs in various cancers, inducing silencing of 
tumour suppressor genes e.g. CDH1 in breast, bladder and prostate cancer (Graff et al. 
1995), CDKN2A in many epithelial cancers (Merlo et al. 1995), and the Rb gene in 
retinoblastomas (Sakai et al. 1991). 
 
Control of gene expression/repression is important in cell development and 
differentiation to ensure that only cell-specific genes are transcribed. Some genes are 
constitutively transcribed in almost all cells, e.g. Glyceraldehyde 3 phosphate 
dehydrogenase (GAPDH); some genes are only transcribed in certain cell types, e.g. 
carnitine palmitoyltransferase I C in rat brain and testes (Price et al, 2002); others are 
only transcribed after a signaling cascade has been initiated, e.g. induction of insulin 
gene transcription by glucose in beta cells of the Islets of Langerhans (Leibiger et al. 
1998).   Eukaryotic DNA is packaged into a nucleoprotein complex called chromatin 
that is organized into two structurally distinct domains, euchromatin and 
heterochromatin (Heitz, 1928). Euchromatin is condensed during cell division but more 
open and transcriptionally active during interphase while heterochromatin is tightly 
packed and transcriptionally inactive throughout the cell cycle.  While there is only one 
class of euchromatin, heterochromatin has two variants, constitutive or facultative.  
Constitutive heterochromatin is fixed, irreversible and located at very specific spots in 
the genome that consist of DNA that contains many tandem (not inverted) repeats of a 
short repeating unit known as satellite DNA.  Facultative heterochromatin can revert to a 
euchromatin state for example, when a woman transmits the X-chromosome to a son; it 
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reverts to euchromatin from heterochromatin.   Replication of these two types of 
chromatin occurs at different time points, with heterochromatic DNA late and 
euchromatic DNA early within the cell cycle (Gilbert, 2002).  DNA methylation is 
functionally connected to these two states through histone modification.  In a simplified 
view, euchromatic DNA contains non-methylated CpGs and the histones are often 
acetylated whereas the CpGs in heterochromatin DNA are methylated and the histones 
are deacetylated with methylation occurring at histone 3 lysine 9 (H3K9m) (Cameron et 
al. 1999).  De-methylation of CpG motifs allows H3K9m to be re-acetylated (Bachman 
et al. 2003) which ultimately leads to a switch from hetero- to euchromatic DNA.  Thus 
DNA methylation is a pivotal signal for the epigenetic control of gene expression in a 
reversible heritable manner. 
 
1.2 Chromatin Structure 
The Basic building blocks of Chromatin are five types of proteins called histones which 
contain a high proportion of charged amino acids.   These histones fall into two 
categories, the nucleosomal histones and the H1 histones.  The nucleosomal group is 
made up of four histones which are called H2A, H2B, H3, H4 and their variants.  They 
are small proteins 102-135aa with H3 and H4 histones being among the most highly 
evolutionally conserved of all proteins.  The H1 histones are larger, approx 220aa, and 
are less conserved than the nucleosomal group.   Although histones are the building 
blocks of chromatin, there are also architectural proteins that are comprised of acidic or 
non-histone chromatin proteins. 
 
The 11 nm diameter nucleosome (Fig.1.1), the fundamental building block of chromatin, 
is a complex comprised of an 146 bp (base pair) length of DNA wrapped around an 
octomer core of histone proteins consisting of two copies each of H2A, H2B, H3, and 
H4 (Richmond et al. 1984, Dorigo et al. 2004).   
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Figure 1.1 X-ray crystal structure of the nucleosome core particle solved by Luger et 
al  (1997).  Ribbon traces for the 146-bp DNA phosphodiester backbones (Yellow) and 
eight histone protein main chains (orange: H3; red: H4; green: H2A; blue: H2B).  Image 
generated from PDB ref 1AO1 (Figure prepared using PyMol).  
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With a small length, 10-100bp, of DNA (linker) between each nucleosome, this type of 
chromatin thread can be visualized by electron microscopy which gives rise to the 
‘beads on a string’ structure description. The H1 histone protein binds to a specific 
region of the nucleosome and mediates the packing of the 11nm nucleosome into a 30nm 
chromatin fibre.  From this 30nm fibre the DNA can be condensed into a chromosome. 
The histones also possess N- and C- terminal tails, 14-38aa in length, that protrude from 
the nucleosome (Luger et al. 1997) and direct the formation of higher-order chromatin 
structures (Dorigo et al. 2003, Dorigo et al. 2004, Gordon et al. 2005). 
 
As mentioned previously not all proteins associated with chromatin are histones.  These 
non-histone architectural proteins are responsible for the chromatin regulatory 
mechanisms such as covalent histone modifications or ATP-dependent chromatin 
remodeling (Cosgrove et al. 2004, Smith & Peterson, 2004, Studisky et al. 2004).  The 
packing of chromatin at its lower level is defined by DNA-histone and nucleosome-
nucleosome interactions.  Chromatin remodeling at specific loci is carried out through 
tagging of the histone tails (Fig 1.2a). Covalent modification of the histone tails in the 
form of acetylation and methylation are important for the remodeling of chromatin to 
activate and repress transcription respectively (Berger, 2001, Strahl and Allis, 2000).  
Other covalent modifications include phosphorylation, ubiquitylation, sumoylation (Gill, 
2004) and ADP-ribosylation (Cohen-Armon et al. 2004) (fig 1.2b) 
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Histone deacetylation (H3K9) by histone deacetylase enzymes (HDAC) and methylation 
of the same residue by histone methyl transferases (HMT) (Fuks et al. 2003) can be 
brought about by the binding of methylated DNA binding proteins to methyl-CpG motifs 
which recruit HDACs to chromatin (Nan X et al. 1998).    The methylation of H3K9 
allows the binding of heterochromatin protein 1 (HP1) via its chromodomain (Banister et 
al. 2001) which stabilizes the formation of heterochromatin and induces transcriptional 
repression.  DNMT1 also binds the HDACs HDAC1 (Robertson et al. 2000) and 
HDAC2 (Rountree et al, 2000) via its N-terminal domain.  DNMT1 binding to HDAC2 
is associated with binding to another protein, DMAP1 (DNMT1 associated protein) 
which can mediate transcriptional repression (Rountree et al. 2000).  It should also be 
noted that loss of DNMT1 from DNMT1 knockout human cancer cells KO1 results in an 
increase of H3 acetylation and loss of trimethylation of lysine 9.  Also HDACs and HP1 
no longer interact with histone H3 and pericentrometric repetitive sequences (Espada et 
al. 2004).  This suggests that DNMT1 contributes more to heterochromatin formation 
than just the methylation of CpG motifs. 
Figure 1.2 a Diagram of the 11 nm beads on a string chromatin conformation 
showing histone tails. b The various histone tail covalent modifications. A , acetyl ;  P, 
phosphate;  M, methyl;  Ub, Ubiqutin; C, carboxy terminus; N, amino terminus.  
Adapted from Marks et al (2001)  
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1.3 DNA Methylation 
Methylation is the major covalent modification of eukaryotic DNA and almost always 
found in a palindromic CpG sequence such that the 5 methyl cytosine is found 
symmetrically on both strands (Sinsheimer 1955).  Methylated DNA was first proposed 
by Scarano (1971) and later by Holliday & Pugh (1975) and Riggs (1975) to be involved 
in cell differentiation and gene function.  Later Yeivin and Razin (1993) showed that 
epigenetic control of gene expression in mammals involves DNA methylation associated 
with gene-specific methylation patterns.  Methylation occurs at 70-80% of mammalian 
CpG sites (Ehrlich and Wang 1981) with the remaining unmethylated CpG sites being 
found in CpG rich islands.  CpG islands have been shown to be present at promoter 
regions of all constitutively expressed and approximately 40% of tissue specific genes 
(Larsen et al, 1992. Zhu et al, 2008).  However, not all CpG islands are non-methylated, 
some of which are involved in X-inactivation and genomic imprinting (Edwards & 
Ferguson-Smith, 2007., Reik, 2007) 
 
Without the replacement of methylated cytosines, DNA replication would remove 50% 
of methylated CpG from DNA after two rounds of replication through passive 
demethylation.  In order to protect the symmetrical methylation of CpG, the enzyme 
DNA methyl transferase (DNMT1) catalyses the covalent attachment of a methyl group 
to the naked cytosine in a hemi-methylated CpG (Bestor and Ingram 1983). DNMT1 is 
associated with proliferating cell nuclear antigen during DNA replication at the 
replication foci, with methylation occurring within one to two minutes of replication to 
restore a state of full methylation to the DNA (Chuang et al. 1997).  It is through this 
process that methylated DNA induced gene repression is inherited from mother to 
daughter for many generations of actively dividing cells (Razin and Riggs 1980).   
 
The reason that CpG Islands are not methylated at replication could be explained by 
their replication during G1/early S phase (Delgado et al. 1998) when DNMT1 levels are 
low (Szyf et al, 1991) and levels of the transcription factor p21 are high which could 
out-compete DNMT1 for binding to PCNA (Chuang et al. 1997).   This could prevent 
DNMT1 being present at the replication foci of CpG islands thus preventing their 
methylation.  This theory is strengthened by the fact that many CpG islands are also 
replication origins (Delgado et al. 1998) and, due to the proteolytic factors involved in 
DNA replication, could block DNMT1 access to the DNA. However, it does not explain 
the lack of methylated CpG islands that are located in the promoters of genes that lack 
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p21 recognition sites.  Recently the CXXC Finger Protein 1 (CFP1), a component of the 
SET1 H3K4 methyltransferase complex (Skalnik et al, 2008), has been shown to bind 
CpG islands (Thompson et al, 2010).  Methylation of H3K4 is a euchromatic mark 
associated with transcriptional activity (Bernstein et al, 2002., Santos-Rosa et al, 2002., 
Schneider et al, 2004).  Therefore the recruitment of CFP1 to CpG islands and 
subsequent methylation of H3K4 may prevent methylation through steric interference.   
 
It has been reported that methylated DNA does undergo active demethylation (Oswald et 
al, 2000) but this is not necessarily associated with replication (Kafri et al. 1992) while 
the paternal genome in fertilized mouse eggs is stripped of DNA methylation prior to 
zygotic fusion and subsequent replication (Mayer et al. 2000).  This demethylation of 
the paternal genome is a feature of mouse, rat, human and pig zygotes but surprisingly 
not of rabbit and sheep zygotes (Beaujean et al. 2005, Beaujean et al. 2004a, Young & 
Beaujean, 2004).  Interestingly the sheep paternal genome is significantly demethylated 
when injected into mouse oocytes (Beaujean et al. 2004b) suggesting it is not inherently 
resistant to demethylation.  While DNMT1 is responsible for maintaining methylation 
patterns during DNA replication, de novo methylation at previously unmethylated sites 
during early embryogenesis is catalyzed by DNMT3a & DNMT3b (Okano et al. 1999).  
However, DNMT1 can be stimulated to methylate CpG dinucleotides by the addition of 
fully methylated DNA (Fatami et al, 2001, Laing et al, 2001).  DNMT1 is essential for 
mouse embryogenesis as targeted knockouts of DNMT1 results in death around mid 
gestation (Li et al. 1992, Bird & Wolffe, 1999). This is also true for Xenopus laevis 
embryos which die before mid-blastula transition if DNMT1 is knocked out (Stancheva 
& Meehan, 2000).  However, this is independent of DNMT1’s methyltransferase activity 
(Dunican et al, 2008)      
 
Aberrant DNA methylation is of particular importance in cancer (Jones & Baylin, 2002) 
as hypomethylation can result in the inappropriate expression of genes while 
hypermethylation of CpG islands can switch off genes (Jones & Baylin, 2002, Feinberg 
& Vogelstein, 1983).  Hypermethylation of CpG islands found in tumor suppressor gene 
promoters is a prevalent mechanism for the transcriptional silencing of these genes 
(Robertson, 2001, Rountree et al. 2001. Esteller & Herman, 2002., Jones & Baylin, 
2002.).  Removal of methyltransferase activity from the human colorectal cancer cell 
line HCT116 by genetic (antisense/siRNA against DNMT1 RNA) or pharmacologic 
methods (5-aza-2'-deoxycytidine) causes extensive hypomethylation throughout the 
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genome, including hypermethylated regions (Robert et al. 2003, Ting et al. 2004).  
However, controversy surrounds the question of knocking out DNMT1 is sufficient for 
this observed hypomethylation event.  Ting et al. (2004) suggest that DNMT1 is 
redundant due to a compensatory role for DNMT3b.  In order to investigate this they 
produced a double knockout of DNMT1 & DNMT3b cells which showed greater than 
95% reduction in genomic methylation and crucially these cells re-expressed the tumour 
suppressor gene Cdkn2a, providing a direct link between the methylation of its promoter 
and its transcription.  These double knockout cells had a 90% reduction in growth 
compared to the wild type HCT116 cells.  DNMT1 might also be targeted to methylate 
DNA at Histone H3-K9 methylated chromatin via interaction with the histone 
methyltransferase SUV39H1 (Fuks et al. 2003).  
 
Females contain two copies of the X chromosome compared the male having just one. In 
order to compensate for this random inactivation of one copy occurs during early 
development (Lyon, 1961).  This inactivation is associated with widespread DNA 
methylation (Heard et al. 1997), while transcription of genes on the inactive 
chromosome can be reactivated when cells are treated by inhibitors of DNA methylation 
(Boumil & Lee, 2001).  Not all gene transcription on the inactive X chromosome is 
silenced as some CpG islands remain unmethylated (Heard et al. 1997). 
DNA methylation plays a critical role in genomic imprinting, the phenomenon whereby 
a small subset of all the genes in the genome are expressed according to their parent of 
origin (Bartolomei & Tilghman, 1997).  The control the reciprocal parental gene for 
almost all imprinted genes identified to date is associated with differentially methylated 
regions (Paulsen & Ferguson Smith, 2001).   
 
Thus DNA methylation states play an important role in the transcriptional repression of 
genes, regulation of chromatin structure and the development of embryos while aberrant 
DNA methylation can cause disease, including cancer & developmental disorders, and 
death during gestation.   
 
1.4 Methylated DNA binding proteins 
MeCP2, MBD1, MBD2, MBD3 and MBD4 constitute a family of proteins which 
contain the methyl-CpG-binding domain (MBD).  In the late 1980s a nuclear factor 
called MeCP1 (Methyl CpG binding Protein) was discovered.  This factor could 
discriminate between DNA molecules that contained 12 or more methylated CpG pairs 
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and unmethylated DNA in band shift assays (Meehan et al. 1989). MeCP1 is a large 
multi-subunit protein complex and has been shown to be comprised of MBD3 (Zhang et 
al. 1999), the Mi2/NuRD complex and MBD2 (Ng H et al. 1999, Feng and Zhang  
2001).  More recently other methyl-CpG binding proteins have been discovered.  The 
zinc finger proteins Kaiso (Daniel and Reynolds, 1999., Prokhortchouk et al, 2001), 
ZBTB4 and ZBTB38 (Filion et al, 2006) and UHRF1 & -2 that contain an SRA (SET 
and Ring finger-associated) domain (Unoki et al, 2004).   The first well characterized 
member of the MBD family is MeCP2.   
 
1.4.1 MeCP2    
Identified in 1992, MeCP2  is a 53kDa protein capable of binding one methyl-CpG pair 
(Lewis et al. 1992) although it is suggested that, in vitro, a flanking run of 4 or more A/T 
base pairs (Klose et al. 2005) enhances the affinity.  This is backed up by analysis of the 
binding sites in two of its known targets, Bdnf and Dlx6, which show the methyl-CpG 
site flanked by an A/T greater than 4 motifs (Klose & Bird 2006).  Levels of MeCP2 
protein vary depending on cell type with rat brain containing the highest followed by 
kidney, spleen, liver with the lowest found in testes (Nan X et al. 1993).  Although 
widespread, MeCP2 is not a major repressor of gene regulation (Tudor et al. 2002) but 
binds to loci not targeted by other MBDs (Klose et al. 2005).  However, these reports 
used cultured neurons from embryonic or immature mice where MeCP2 levels are low.  
Skene et al (2010) determined the binding pattern in mature mouse brains which showed 
a different pattern, with MeCP2 tracking the methyl-CpG density of the genome.  These 
results suggest, in mature mouse brain, that MeCP2 is a global regulator of chromatin 
structure.   
 
The MBD domain, defined as the minimum required to bind methyl-CpG, comprises 
amino acids 78-162.  This MBD domain has similar characteristics of the full length 
protein when binding methyl-CpG DNA in that it will bind a single methyl-CpG motif in 
duplex DNA and has negligible binding to hemimethylated DNA or 5-methylcytosine at 
non-CpG motifs (Nan X et al. 1993).  Within mouse EB28/10 cells, MeCP2 shows 
punctate labeling, co-localising with heterochromatin when transiently over expressed.  
This localisation to the chromatin is dependant on methylation, as over expressed 
MeCP2 in MTase mutant (methylase negative) mouse ES cells produced diffuse nuclear 
staining with only 20% localizing to chromatin (Nan X et al. 1996).  The small 
percentage of MeCP2 binding to chromatin is likely to be due to the lower levels of 
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methyl-CpG remaining (Nan X et al. 1996) and non specific DNA binding (Nan X et al. 
1993).     Once bound to methylated CpG, MeCP2 initiates transcriptional repression by 
recruiting the transcriptional co-repressor Sin3 and histone deacetylase (HDAC) 
complex (Nan X et al. 1998).  Binding of the HDAC is via a transcriptional repression 
domain (Nan X et al. 1997) and is localized to amino acids 207–310 (Yu et al. 2000).  
Removal of the acetyl group from histone H3 lysine 9 (Nan X et al. 1998) facilitates the 
methylation of the same residue by a histone methyltransferase (HMT) (Fuks et al. 
2003).  Treatment with trichostatin A (an inhibitor of HDAC), however, does not fully 
remove transcriptional repression which suggests that MeCP2 can repress by another 
pathway (Yu et al. 2000) or interaction with other complexes that do not require HDAC 
to inhibit transcription.     
 
1.4.2 MBD1 
Cross et al. (1998) identified MBD1 (formerly PCM1) by searching the XREF database 
for sequences homologous to the MBD of MeCP2. MBD1 was shown to bind methyl-
CpG via its MBD.  MBD1 was originally thought to be part of the MeCP1 complex 
(Cross et al. 1998).  However, Huck-Hui et al. (2000) showed that MeCP1 band shift 
assays were not affected when MBD1 was immunoprecipitated using a sheep antibody 
against MBD1 amino acids 351-556 from the extract.  As well as the N-terminal MBD 
domain, MBD1 also contains, depending on alternative splicing, 2 or 3 CXXC domains 
(Fujita et al, 1999, Jørgensen et al, 2004).  There are a total of 8 known isoforms of 
MBD1 with the number and type of CXXC domains shown in figure 1.3 
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Figure 1.3 schematic representations of MBD1 splice variants with different 
combinations of CXXC domains.  A: represents isoforms 1, 2, 6, 8; B: represents 
isoforms 3, 4 ,7; C: isoform 5 (formerly known as PCM1). 
 
A subunit of CAF-1 (chromatin assembly factor 1), p150, and SUV39h1, a 
methyltransferase enzyme both interact with the MBD (Fujita et al. 2003b, Resse et al. 
2003).  It is thought that MBD1 is displaced from methyl-CpG during replication but 
that through its interaction with CAF-1 via PCNA, it remains at the replication fork 
during S-phase.  Once replication has occurred, DNMT1 activity fully methylates 
hemimethylated CpG motifs allowing MBD1 to rebind to the methyl-CpG (Sarraf & 
Stancheva, 2004) (Fig. 1.4)  
 
Like MeCP2, MBD1 contains a transcriptional repression domain which, when fused to 
the Gal4 DNA binding domain, can repress transcription from a Gal containing 
promoter.  The transcriptional repression domain (TRD) is known to interact with a 
methyl-DNA glycosylase (Watanabe et al. 2003) and MCAF (MBD1-containing 
chromatin associated factor) (Fujita N et al. 2003a).   Although MBD1 does not appear 
to interact with HDAC1 or HDAC2 (Ng H et al. 2000) there is variable repression 
sensitivity when cells are treated with the HDAC inhibitor trichostatin A (Ng H et al. 
2000, Fujita N et al. 2003a) suggesting that MBD1 induced repression does not always 
require HDACs 
 
Although MBD1 knock out mice have been produced, the MBD1-/- mice show no 
detectable development defects and appear physically healthy throughout their life span.  
However, adult knockout mice show decreased neurogenesis and impaired spatial 
TRD MBD 1          2         3  
CXXC 
TRD MBD 1          2          
CXXC 
TRD MBD             2         3  
CXXC 
A 
B 
C 
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learning, while neural stem cells exhibited reduced neural differentiation and increased 
genomic instability (Zhao et al. 2003). 
 
 
 
 
 
 
 
 
1.4.3 MBD2 
MBD2 was identified by Hendrich & Bird (1998) by searching for putative MBD 
domains in the EST database.  It has two possible isoforms depending on translation 
from the first (MBD2a, 43.5 kDa) or second (MBD2b, 29.kDa) ATG codon.    The 
translation from the second ATG codon produces a protein with the MBD at the extreme 
N-terminus (Hendrich & Bird, 1998) lacking the glycine rich region found in MBD2a 
(figure 1.5).    
 
 
 
 
Figure 1.4. Model summarizing the function of MBD1 complexes in  
transcriptional repression and DNA replication-coupled maintenance of histone 
H3-K9 methylation. MBD1 and H3-K9 methylase SETDB1 form a stable 
MBD1/SETDB1 complex detectable throughout the cell cycle in G1, S, and G2 
(Reproduced from Sarraf & Stancheva, 2004) 
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Figure 1.5. Schematic representation of the two isoforms of MBD2. 
 
It was proposed that MBD2b has DNA demethylase activity (Bhattacharya et al. 1999) 
but subsequent attempts by Ng et al. (1999) and Wade et al. (1999) were unable to 
reproduce these results.  Like MeCP2, transcriptional repression via MBD2 occurs 
through histone modification and it was proposed that MDB2 is part of the MeCP1 
complex (Ng et al. 1999) which comprises MBD3 (Zhang Y et al. 1999) and the 
Mi2/NuRD complex (Feng Q and Zhang Y 2001). Recently however, Guezennec et al. 
(2006) have suggested that MBD2/Nurd and MBD3/Nurd are two distinct complexes.  
Evidence to further back up Guezennec’s results is shown in MBD2 and MBD3 
knockout mice.  While MBD3-/- mice die during early embryogenesis, MBD2-/- mice are 
viable and fertile suggesting distinct but overlapping roles for MBD2 & MBD3.  
Although MBD2-/- mice are viable, they show a lack of maternal instinct that results in 
reduced pup weight (Hendrich et al. 2001).  When MBD2-/- mice are crossed with 
Apcmin/+ mice, the offspring show reduced adenoma and extended life span compared to 
normal Apcmin/+ mice (Berger & Bird. 2005).   
 
It has been shown that MBD2 interacts with the NuRD complex via a 633 aa protein 
called p66 (Brackertz et al. 2002).  This interaction between p66 and MBD2 has been 
shown to involve two domains.  In p66 aa134-238 (CR1) & aa372-633 (CR2), with the 
second sequence also containing a Zinc finger GATA domain.  In MBD2 the domains 
aa27-45 and aa211-262 bind p66 in a pull down assay (Brackertz et al. 2002).  The 
MeCP1 complex also contains p68 which has high amino acid similarity to p66.  p68 
also interacts with MBD2 but only through the highly conserved CR1 N-terminal 
binding site.   
 
1.4.4 MBD3 
Human MBD3 is a 265 amino acid 32.2kDa protein with an N-terminal MBD domain 
and a C-terminus rich in acidic residues.  It is has a high sequence similarity to MBD2b 
MBD Glycine rich 
MBD2a 
MBD 
MBD2a 
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although unlike other members of the MBD family it does not bind methyl-CpG in vitro 
or localize with major satellite DNA in vivo (Hendrich & Bird. 1998).  Similarly it does 
not possess DNA demethylase activity (Wade et al. 1999).   Unlike the human form, 
Xenopus laevis xMBD3 binds methyl-CpG (Wade et al. 1999).  Xenopus laevis also 
expresses an isoform xMBD3LF, a product of alternative spicing with a sequence of 20 
amino acids inserted in the MBD domain, which cannot bind methyl-CpG (Wade et al. 
1999).  xMBD3 is expressed constitutively in the early stages of development with high 
levels detected in the prospective eye regions, brain, and branchial arches.  Suppression 
of xMBD3 in early development severely effects eye formation and brain development 
(Iwano et al. 2004).  Although MBD3 does not bind methyl-CpG it does co-purify with 
the histone remodeling complex Mi-2/NuRD (Guezennec et al. 2006). This coupled with 
the fact that MBD3-/- knockout mice are non-viable, dying during early embryogenesis 
(Hendrich et al. 2001), suggests that MBD3 plays an important role in early 
development like that of xMBD3.  While the MBD domain of MBD3 does not bind 
methyl-CpG it does bind HDAC and metastasis-associated gene 2 (MTA2) (Saito & 
Ishikawa, 2002).  This suggests that MBD3 has conserved its MBD because of the 
secondary role played by the MBD in protein-protein interactions. 
 
1.4.5 MBD4 
MBD4 was identified at the same time as MBD2 and MBD3 by Hendrich & Bird 
(1998).  This 62.6kDa protein has its MBD domain at the N-terminus and lacks the 
CXXC domains of MBD1.  Like MBD1, MBD2 and MECP2, MBD4 can also bind to 
one symmetrically methylated CpG.  The MBD is most similar to that of MeCP2 in 
sequence and the protein shows little homology to the other MBD family members out 
with the MBD domain. MBD4 does however share a low scoring match to bacterial 
DNA repair enzymes.  (Hendrich & Bird, 1999).  As well as the N-terminal MBD 
domain, MBD4 contains a C-terminal DNA glycosylase catalytic domain  (Hendrich & 
Bird, 1999, Bellacosa et al. 2005) and it has been shown that MBD4 is a thymine and 
uracil glycosylase specific for G-T and G-U mismatches resulting from the deamination 
of 5-methylcytosine and cytosine, respectively, at CpG sites (Hendrich et al. 1999).  
MBD4 is expressed in many human tissues and MBD4-GFP constructs co-localise to the 
foci of heavily methylated satellite DNA (Hendrich & Bird, 1998).  Results from MBD4 
deficient mice suggest that MBD4 suppresses tumorigenesis and CpG mutability in vivo 
as there is an increase in CpGTpG mutation and accelerated tumor formation in cancer 
susceptible Apcmin/+ mice (Miller et al. 2002). 
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 1.4.6 MBD domain structures 
There several MBD domain structures that have been deposited in the protein data bank.  
The solution structure of MBD1 MBD (Ohki et al. 1999), MBD1 MBD in complex with 
DNA (Ohki et al, 2001), solution structure of MeCP2 MBD (Wakefield et al. 1999) and 
the crystal structure of MeCP2 MBD in complex with DNA (Ho et al, 2008) have been 
solved. The NMR derived structures for MBD1 MBD and MeCP2 MBD show similar 
structures consisting of a wedge shaped fold with four anti-parallel β-strands which 
constitute one face of the wedge.  Comparison of the crystal structure of MeCP2 in 
complex with DNA (PDB 3C21) and the unliganded NMR structure of MeCP2 (PDB 
1QK9) illustrated in figure 1.6 reveals little difference apart from the loop (L1) where 
most of the protein to DNA sugar-phosphate backbone contacts are made.  While there 
is only moderate homology between MBD1 and MeCP2 there are conserved residues 
within the MBD of the whole family.  It is likely that the MBD of MBD2, MBD3 and 
MBD4 have similar structures.  The lack of binding to methyl-CpG by mammalian 
MBD3 can be attributed to two amino acid differences within the defined MBD domain, 
a phenylalanine at position 34 in place of a tyrosine and a histidine at position 30 in 
place of an arginine (MBD1 & MBD4) or a lysine (MBD2 & MeCP2) (Saito &, 
Ishikawa. 2002). The effect of the F34 difference has the greatest effect on mCpG 
binding.  This is not surprising due to the interaction of the tyrosine side chain hydroxyl 
group hydrogen bonding to structural water groups that are involved in the protein-DNA 
interaction. 
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Figure 1.6 Superposition of unbound MeCP2 (green) and MeCP2 bound to DNA 
(yellow).  Methyl-cytosine (sticks) shown as cyan on DNA shown in orange (ribbon), 
Tyrosine 34 shown in red (sticks) and the structural water shown as a black sphere. N, 
N-terminus. Image generated in pymol.   
 
1.4.7 The Zinc finger family of methyl-CpG binding proteins 
The first member of the zinc finger family of mCpG binding proteins, Kaiso, was 
identified by a yeast 2 hybrid screen for p120 catenin (Daniel and Reynolds, 1999) and 
is a component of the NCoR corepressor complex binding via its BTB domain (Yoon et 
al, 2003) Kaiso contains three tandem zinc fingers at the C-terminus that recognize two 
consecutive symmetrical CpG sequences. In cultured cells, Kaiso recruits the NCoR 
complex to the MTA2 promoter when methylated.  This results in transcriptional 
repression with H3 K9 being deacetylated and methylated (Yoon et al, 2003).  Although 
in normal cells there is presently no information about the target of Kaiso, it is essential 
for amphibian development.  When embryonic levels of the Xenopus Kaiso homologue, 
xKaiso (Kim et al, 2002), are depleted by morpholino oligos, premature activation of 
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zygotic genes occurs before the mid-blastula transition, resulting in failure of 
gastrulation and death (Ruzov et al, 2004).  Kaiso also binds to a non-methylated DNA 
sequence, TCCTGCNA, known as a Kaiso-Binding Sequence (KBS) (Daniel et al, 
2002). This KBS sequence has been found in the promoter of matrilysin (Spring et al, 
2005) and the 5’ beta-globin insulator (Defossez et al, 2005).  The proteins ZBTB4 & 
ZBTB38 (Filion et al, 2006) contain a homologous Kaiso zinc finger domain, which also 
contain a BTB domain but also have additional zinc fingers making them longer and 
more complex.  Unlike Kaiso, the ZBTB proteins can bind a single methylated-CpG 
which may be due to sequence differences compared to Kaiso within the 3rd Kaiso like 
zinc finger although their in vivo targets are as yet unknown.  ZBTB38 has been shown 
to recruit CtBP to the densely methylated pericentrometric heterochromatin (Sasai et al, 
2005).   CtBP is a corepressor which has also been found to interact with the CXXC 
domain from MLL (Mixed Linkage Leukemia) (Xia et al, 2003) and can induce 
transcriptional repression by recruiting HDACs (Subramanian & Chinnadurai, 2003).  
Unlike ZBTB38, ZBTB4 lacks the CtBP interaction site and the BTB domain is 
disrupted by a long serine-rich insertion (Perez-Torrado et al, 2006). 
 
1.4.8 Methylated CpG binding by the SRA domain 
 UHRF1 was originally identified by Hopfner et al (2000) as CCAAT box binding 
protein before Unoki and co workers (2004) showed that UHRF1 could bind methylated 
CpG with higher affinity.  The SET and Ring finger associated (SRA) domain of 
UHRF1 is responsible for recognizing a single methylated CpG and interacting with 
HDAC1 (Unoki et al, 2004).  Recently Bostick et al (2007) showed UHRF1 has a 
preference for hemi-methylated DNA and that UHRF1 co-localizes with 
heterochromatin replication foci and interacts with DNMT1 & PCNA, suggesting a role 
in the transfer of heritable transcriptional repression similar to that of MBD1.   
 
1.5 Epigenetic Disease 
Many cellular processes including embryonic development, transcription, chromatin 
structure, X chromosome inactivation, genomic imprinting and chromosome stability are 
controlled by epigenetic mechanisms.  Any disruption to these processes will have a 
profound effect on the cell and the organism. A common disruption in humans (1:10,000 
births) is Rett Syndrome, a complex neurological disorder mainly affecting girls who 
become profoundly and multiply disabled.  In a large proportion of patients this has been 
linked to mutations in MeCP2 (Amir et al, 1999).  Epigenetic disruption is common in 
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many cancers with the tumour cells displaying global hypomethylation but having 
hypermethylated CpG islands in conjunction with histone modifications that 
repress/silence tumour suppressor genes (Fahrner et al. 2002, Ballestar et al. 2003).   
 
1.5.1 Rett syndrome  
Rett syndrome is both sporadic and familial in origin with various mutations found 
within the gene responsible for its aberrant activity. Amir et al. (1999) identified 
missense mutations within the highly conserved MBD region as well as missense and 
frame shift mutations within the TRD region while further novel mutations were 
identified by Wan et al. (1999) & Cheadle et al. (2000).   A recent review by Matijevic 
at al (2009) noted that 67% of all MeCP2 mutations are caused by a C>T mutation at 
8CpG sites (R106, R133, T158, R168, R288, R270, R294 and R306) the most common 
of which is R168X.     
 
The various mutations of MeCP2 (nonsense, missense, and frame shift) vary the level of 
functionality that the protein has.  Nonsense and frame shift mutations in the 5’ region 
are likely to lead to unstable transcripts through the process of nonsense-mediated decay 
(Dragich et al. 2000) while several missense mutation show reduced binding to mCpG in 
vitro (Ballestar et al. 2000).  Two common mutations, R106W & R133C, are located 
within the β-sheet (Wakefield et al. 1999) and show 100 fold reduction in affinity for 
binding methylated DNA in unassembled chromatin (Ballestar et al, 2000).  However in 
native mouse heterochromatin only R106W had markedly reduced binding, whereas 
R133C showed wild-type-like affinity and increased repression of a non-methylated 
reporter construct in Drosophila cells (Kudo et al. 2001). This increased affinity for non-
methylated CpG in the R133C mutant may be party due to the alteration of the DNA 
binding site since R133 is completely conserved between MBD family members while 
mutation of this arginine to an alanine in MBD1 abolishes binding to mCpG (Ohki et al. 
1999).   Another common mutation, T158M, found in the loop structure of the MBD, 
showed only a 2-fold reduction in the binding to methylated DNA while it retained 
partial affinity for heterochromatin (Kudo et al. 2001).   Disruption of mCpG binding 
and the ability of MeCP2 to interact with HDACs will affect the role of MeCP2 in 
transcriptional repression.    The brain has the highest abundance of MeCP2 compared to 
any other tissue (Nan et al. 1997) which might suggest that brain tissue is highly 
susceptible to abnormalities arising from aberrant gene expression.  This idea is 
supported by work carried out in 2000 by Cheadle et al. who noted that patients with 
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missense mutations had significantly milder disease compared to those with truncated 
isoforms.  This may be due to truncation abolishing MeCP2’s ability to interact with 
Sin3A and recruit histone deacetylase to repress transcription through its TRD (Jones et 
al, 1998, Nan et al, 1998).  However, since inhibition of histone deacetylase activity by 
the drug Trichostatin A only partially relieves transcriptional repression by the TRD 
suggesting the TRD can mediate repression in a histone deacetylase independent manor 
(Jones et al, 1998, Nan et al, 1998).  This may not be the only mechanism.  
 
1.5.2 Disease associated with other MBD proteins 
MBD1, 2, 3 do not have any known disease/syndrome associated with mutations in their 
genes.  Knockout mice have been produced for all except MBD3 for which knockout is a 
lethal genotype.   MBD1 knockout mice show no obvious development abnormalities 
and appeared healthy throughout their life.  However, their neural stem cells exhibited 
reduced neuronal differentiation, increased genomic instability and deficits in adult 
neurogenesis and hippocampal function (Zhao et al, 2003) indicating that MBD1 maybe 
important for normal brain function.  As a consequence of knocking out MBD2,  
MBD2-/- mice appear to suffer post natal depression but no other physical or mental 
abnormalities (Hendrich et al. 2001).  MBD4 knockout mice suffer increased (3-fold) C 
to G mutations particularly at mCpG sites and when crossed with the ApcMin/+ mouse the 
resultant Mbd4 / , ApcMin/+ litter have increased levels of intestinal neoplasia when 
compared to ApcMin/+ (Miller et al. 2002).   
 
While there are no disease syndromes attached to the MBD1-3 proteins, MBD4 has been 
shown to be mutated in colorectal tumours (Bader et al. 1999) and primary gastric 
cancer (Yamada et al. 2002).  However, expression levels of these proteins have been 
shown to vary in cancer cell lines and tissue.  Patra et al. (2003) compared the 
expression of MBD1, MBD2 and MECP2 in prostrate and BPH cancer cell lines.  They 
found protein expression levels of MBD1 increased in the cancer cells compared with a 
BPH (human prostatic epithelial) cell line, with the protein levels of MBD2 & MeCP2 
being repressed at the translation step, while levels of DNMT1 and HDAC1 where 
significantly increased. MBD1 has been shown to repress transcription of the p16 
tumour suppressor gene (Hendrich et al. 1999) although levels of this protein where not 
analysed.  
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1.5.3 Disease associated with Hypermethylation 
Hypermethylation of CpG islands occurs within the promoter regions of many critical 
cancer genes (Baylin et al. 1999, Esteller et al. 2001, Billard et al. 2002) which leads to 
transcriptional repression.  The promoter region of the π-class glutathione S-transferase 
gene, GSTP1, has been shown to be hypermethylated in >90% of prostate cancers (Lee 
et al. 1997, Lin et al. 2001.), >70% in liver cancers (Tchou et al. 2000) and >30% in 
breast cancer (Esteller et al. 1998).  The reduction in gene transcription has been 
attributed the hypermethylation event as treatment of the cells with inhibitors of DNMT1 
increased both GSTP1 mRNA and protein levels (Lin et al. 2001, Singal et al. 2001).  
Using siRNA techniques Lin & Nelson (2003) knocked down the transcription of MBD2 
(~79%), DNMT1 (~83%) & MeCP2 (~77%) in MCF-7 (breast cancer) cells and 
recorded an increase in transcription of GSPT1 from only the MBD2 and DNMT1 
siRNA treated cells.  DNMT1 and MBD2 have also been detected bound to the 
hypermethylated GSTP1 promoter in MCF-7 cells using ChIP assays (Lin & Nelson, 
2003) but it is unknown if DNMT1 is repressing transcription although the recruitment 
of DNMT1 to the GSTP1 promoter is dependent on the methylation of the CpG island 
(Lin & Nelson, 2003).  These data suggest that both MBD2 and DNMT1 are involved in 
aberrant transcriptional repression of GSTP1 in the MCF-7 cell line although the exact 
role of DNMT1 has not been described at this time.   
 
MBD2 expression has been studied in other cell lines.  Billard et al. (2002) studied 
MBD2 expression during normal and pathological growth of the human mammary 
gland.  They found that MBD2 expression was 20-30 fold higher in benign tumours than 
normal tissue, but in neoplastic samples MBD2 and MECP2 were deregulated.  It was 
also noted that MBD2 expression varied with tumour size in invasive ductal carcinomas.  
In contrast to the varied transcription in breast cancer, human colorectal, gastric 
cancerous tissues (Kanai et al. 1999) and the peripheral blood lymphocytes in bladder 
cancer patients (Zhu et al. 2004) show a decrease in transcription suggesting there could 
be a protective role for MBD2 in these diseases. 
 
DNMT1 has also been shown to be over expressed in various cancers compared to 
normal tissue (Sun et al. 1997, Kanai et al. 2001, Saito et al. 2001), and that over 
expression correlated significantly with detection of methylated CpG islands (Kanai et 
al. 2001).  However, DNMT1 is expressed mainly during S-phase and because tumour 
tissue is presumed to contain a greater proportion of dividing cells than normal tissue is, 
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the increase in DNMT1 expression could be due to an increase in dividing cells or an 
increase in each cell. 
 
MBD2 and DNMT1 have been implicated as key players in various gastric cancers and 
are therefore targets for anticancer drugs.  MBD2 appears to be the more attractive target 
as knocking out MBD2 does not appear to have any distinct or severe side effects unless 
you are a nursing mouse, and while inhibition of DNMT1 can restore almost wild type 
growth in cell culture it is not without side effects.  The interaction between p66 and 
MBD2 within the MeCP1 complex is an obvious target for drug design.      
 
1.6 Non-methylated CpG and CXXC domains 
The CXXC domain is characterized by a cystine rich CXXCXXC repeat where X is any 
amino acid.  CXXC domains are found in chromatin binding proteins MBD1 (2 or 3 
CXXC domains depending on splice variant), DNA methyltransferase 1 (DNMT1) 
(Bestor 1992), CpG-binding protein (CGBP) (Lee et al. 2001) and the mixed-linage 
leukaemia gene (MLL) (Tkachuk et al, 1992).  The CXXC domain in DNMT1 as been 
shown to bind zinc (Bestor 1992) while the CXXC domain of CGBP has been shown 
require zinc to bind non-methylated CpGs in vitro (Lee et al. 2001).  The 3rd CXXC 
domain in MBD1 has also been shown to bind non-methylated CpG motifs and cause the 
repression of non-methylated reporter genes via the transcriptional repression domain 
while CXXC1 & -2 do not (Jorgensen et al. 2004).  The CXXC domains (1 to 3) from 
MBD1, HRX/MLL, CGBP and DNMT1 show sequence similarity mainly through 8 
cystine residues that form the two zinc clusters (fig 1.7) with CXXC-3 showing further 
homology to CGBP and other non-methylated DNA binding proteins (Jorgensen et al. 
2004).  The CXXC domain sequences shown in figure 1.7 also contain a glycine residue 
succeeding the first cysteine in each cluster (pink)  However, MBD1 CXXC1 and 
CXXC2 lack the  sequence KFGG (and other conserved residues D 31 & Q43) compared 
to the other CXXC domains.   
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Figure 1.7 Alignment of CXXC domains from hMLL (NP_005924), hDNMT1 
(NP_001370.1), hCGBP NP_055408), MBD1 CXXC1, CXXC2, CXXC3 (NP_056671).  
Sequences were aligned using Jalview (Clamp et al, 2004).  Cysteines involved in forming the 
zinc clusters are shaded blue and numbered according to the cluster they participate in.  
Residues conserved between domains than bind non-methylated CpG are shaded green and non 
cysteine common residues between all sequences are coloured pink 
 
As noted above (p6) methylation occurs at 70-80% of mammalian CpG sites (Ehrlich 
and Wang 1981) with the remaining unmethylated CpG sites being found in CpG rich 
islands usually found in the promoter regions of house keeping genes (Bird 1986). It is 
therefore likely that CXXC domains have a role in binding to CpG islands.  Recently 
Thomson et al (2010) showed that CXXC finger protein 1 (CFP1), part of the Setd1 
H3K4 methyltransferase complex (Lee et al, 2007), localize to CpG islands and appears 
to be required for H3K4 methylation, which is normally associated with transcriptionally 
active promoters.  In acute myeloid leukemia the MLL protein is fused with LCX 
(leukemia-associated protein with a CXXC domain) (Ono et al, 2002).  This fusion 
protein is essential for target recognition, transactivation, and myeloid transformation by 
the MLL oncoprotein (Atton et al, 2004).  With a mutated CXXC domain from MLL 
which is unable to bind non-methylated CpG, the MLL/LCX fusion protein is unable to 
induce transcription from target genes.  The direct functions of the CXXC domains from 
MBD1 are currently unknown.  It has been shown that the CXXC domain from DNMT1 
is essential for enzymatic activity and that single point mutations in the CXXC domain 
disrupt the DNA binding ability but do not interfere with DNMT1 targeting to 
replication foci (Fatemi et al, 2001., Pradhan et al, 2008).  CXXC domains also have 
been shown to interact with various proteins involved in chromatin remodeling.  Xia et 
al (2003) investigated the protein-protein interactions of the MLL/LCX CXXC domain. 
Using GST-pull down assays and co-immunoprecipitation they were able to show that 
the CXXC domain interacts with CtBP (C-terminal binding protein) and hPc2 (human 
polycomb 2 protein).  CtBP can meditate transcriptional repression by recruiting HDACs 
(Subramanian & Chinnadurai, 2003) while hPc2 is a member of the PRC1 complex 
(shao et al, 1999).  MLL/LCX CXXC recruitment of PRC1 mediates transcription 
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repression independent of HDAC activity (Xia et al, 2003).  Fuks et al (2000) also 
reported the DNMT1 CXXC domain could mediate HDAC-independent transcriptional 
repression using the Gal4 reporter system.  The MBD1 CXXC3 domain is similar to the 
MLL & DNMT1 CXXC domain in sequence and it can bind non-methyl CpG DNA 
(Jorgensen et al. 2004).  With this similarity in mind, Sakamoto et al (2007) used a yeast 
two hybrid screen to identify proteins that interact with the three CXXC domains from 
MBD1.  They were able to show the MBD1 CXXC3 also interacted with hPc2 while 
CXXC12 interacted with amino acids 250-337 of Ring1b.  Ring1b, like hPc2, is a major 
component of the Polycomb group (PcG) multiprotein PRC1 complex (Min et al, 2003).  
This suggests that although the first two CXXC domains from MBD1 do not bind CpG 
DNA they have a role in transcriptional repression through the interaction of the PRC1 
complex.   
 
The solution structure of the MLL CXXC domain (Allen et al, 2006), MLL in complex 
with DNA (Cierpicki et al, 2009), xDNMT1 (Thomson & Smith, unpublished) and the 
crystal structure of DNMT1 CXXC in complex with DNA (Song et al, 2010) have been 
solved.  The structure of MLL CXXC domain forms a crescent like structure containing 
two zinc atoms.  Each zinc atom is coordinated by 4 cystine residues (figure 1.8).  These 
two zinc atoms are required for structural integrity of the domain since mutation of any 
of the conserved cysteine residues results in an unfolded protein (Allen et al, 2006, 
Cierpicki et al, 2009)     
 
Figure 1.8 Stereo view of the solution structure of the MLL CXXC domain in cartoon 
form (Cierpicki et al, 2009).  Zinc atoms shown as gray spheres, N, N-terminus; C, C-
terminus.  PDB 2KKF (Figure prepared using PyMol). 
N N 
C C 
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Shown in figure 1.9, the MLL CXXC domain binds the CpG motif in the major groove 
though formation of hydrogen bonds from the N4-amine groups of C118 and C106 and 
the backbone oxygen of K1185 and K1186 respectively.  The side chain of K1186 forms 
hydrogen bonds to G119 while the side chain amide of Q1187 hydrogen bonds to G107 
(Cierpicki et al, 2009).   Cierpicki et al (2009) also discovered weak NOEs between the 
side chains of R1150, S1152 and L1197 and the minor groove.  Mutation of R1150 and 
L1197 to alanine resulted in a 5 and 4 fold reduction in DNA binding affinity 
respectively.   
 
 
 
Figure 1.9 Stereo view of the solution structure of the MLL CXXC domain in complex 
with DNA in cartoon form showing the CpG palindrome in red, the DNA backbone in 
orange and the residues involved in DNA binding N, N-terminus; C, C-terminus. PDB 
2KKF (Cierpicki et al, 2009) (Figure prepared using PyMol). 
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CHAPTER TWO 
 
INTRODUCTION PART 2: PROTEIN NMR 
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m – magnetic quantum number 
2.1 Nuclear Magnetic resonance 
In this section the fundamental theory underlying the experiments that I applied in 
investigating MBD1 CXXC1 and MBD1 CXXC12 are outlined.  I have written this 
chapter from the point of view of a biologist using NMR as a technique used to answer 
questions about a proteins function.  As such I hope that a scientist without any 
experience of NMR should be able to follow and understand. 
 
2.1.1 Basic Theory of one dimensional NMR 
Nuclear magnetic resonance (NMR), first described by Felix Bloch and Edward Mills 
Purcell in 1946, is the phenomenon of atoms absorbing radio-frequency electromagnetic 
radiation (RF) under the influence of a magnetic field.  For protein NMR the detection of 
this absorption requires the use of isotopes of carbon, nitrogen and hydrogen which have 
a spin 1/2.  Spin is a quantum mechanical property attributed to protons, neutrons and 
electrons, measured in multiples of ½ and can be positive or negative.  In protein NMR, 
isotopes of carbon, nitrogen and hydrogen that have a nuclear net spin +/- ½.  Nuclear 
net spin ½ occurs when the isotopes have an unpaired proton e.g. 1H, 13C, 15N are used.  
It is a quantum mechanical requirement that nuclei with a spin ½ be in one of two states 
(low or high energy state) when placed in a magnetic field (figure 2.1).  When no 
external magnetic field is applied the two states are of equal energy.  The energies of the 
spin states are split with the application of a magnetic field.  
 
 
 
Figure 2.1 Figure showing the effect on the potential energy of the spin states on a 
nucleus when an external magnetic field is applied.    
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 At equilibrium jumping from one spin state to the other is a relatively infrequent 
occurrence.  However, application of RF energy equal to the difference between the two 
states will generate a greater amount of jumping between states. The frequency of the 
RF energy required for nuclei to absorb radiation is known as the Larmor frequency.  
The Larmor frequency is equal to the frequency of the precessional orbit of the nucleus 
in the applied magnetic field.  After a pulse of RF energy, the spin states of the majority 
of nuclei will under go relaxation to their original state.  This relaxation is known as a 
Free Induction Decay (FID) The energy required to flip the states depends on the 
strength of the magnetic field they are placed in, the type of nucleus e.g. 1H or 13C, and 
the chemical environment of the nucleus e.g. the methyl and hydroxyl protons of 
methanol absorb at different frequencies and the amide protons of two tryptophans in a 
protein are likely to absorb at different frequencies because they are in different 
chemical environments.  This effect is known as chemical shift and is a major source of 
information in NMR spectra for assignment of atom types since protons attached to Cα, 
amide N and side chain heavy atoms have characteristic chemical shifts.  
 
2.2 Homonuclear 1H NMR 
 In protein NMR there are various experiments that can be performed in order to 
elucidate a three dimensional structure.  In essence they fall into 2 categories: through 
bond, where the magnetization is transferred from atom to atom through the intervening 
covalent bonds; and through space, where the magnetization is transferred between 
atoms that are close together (< 5Å apart) but not necessarily covalently linked.  The 
experiments are performed on samples that are either unlabeled or labeled with 13C 
and/or 15N.  NMR structures of small proteins <10kDa can normally be elucidated with 
unlabelled samples using homonuclear NMR, since naturally abundant hydrogen has a 
spin ½ (Wuthrich, 1986). 
 
2.1.1 Water suppression 
The NMR experiments carried out for this thesis were performed in aqueous solutions. 
The concentration of 1H nuclei in water is approximately 110 M compared to 0.5-1.0 
mM for the protein molecules.  This results in ~105 greater equilibrium magnetization of 
water 1H spins.  Without suppressing the signal from the water, detection of the protein 
signal without spectrum distortions is impossible.  By replacing H2O with D20 
(99.999%) as the solvent, it is possible to reduce the H2O resonance signal a factor of 
105.  However, signals from exchangeable, e.g. amide 1H, nuclei will be reduced or 
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absent from the spectra.  Since scalar coupling and dipolar interactions between 
backbone amide 1HN spins with amide 15N and 1Hα spins are required for backbone 
assignment certain NMR experiments must be carried out in an H2O solvent. 
The simplest method of water suppression is presaturation.  A long low powered pulse 
which is applied scrambles the water signal around the applied Z-axis.  The net effect of 
this pulse causes the water signals from different parts of the sample to cancel each other 
out before the main sample pulse sequence is initiated.  Water suppression by 
presaturation is a simple and effective method. However, 1Hα spins close to the water 
signal can be saturated by the RF field and saturation transfer may partially saturate 
exchangeable 1H spins.   A more effective water suppression technique is excitation 
sculpting (Hwang and Shaka, 1995).  This method of water suppression is executed 
before detection of the FID and requires pulse field gradients.  A gradient pulse is first 
applied to scramble the homogeneity of magnetization in the sample.  A selective 180º 
pulsed on water followed by a non selective 180º pulse turns the water through 360º.  
Since the initial magnetization on non-water protons has been turned though 180º a 
second gradient pulse refocuses the non-water signals but not the water.  A variation of 
this excitation sculpting is known as a 3-9-19 watergate.  This type of water suppression 
is more suited to 2D and 3D experiments due to the use of selective pulses that do not 
excite water rather than the water selective and non-selective pulse in the Hwang and 
Shaka (1995) method.  The use of the non-water selective pulses shortens the time of the 
water suppression element in the pulse sequence, reducing the length of time the sample 
has to relax.    
 
2.2.2 1D homonuclear NMR 
A 1D 1H NMR experiment consists of two parts: preparation and acquisition.  In the 
simplest case, shown in figure 2.2, preparation is a 90˚ pulse applied along the x-axis 
which transfers the magnetization from the z-axis into the transverse plane to the 
negative y-axis.  The receiver coil records the signal emitted by the nuclei as they 
precess at their Larmor frequency (figure 2.3)     
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Figure 2.2 Schematic diagram of a simple 1D NMR experiment  
 
 
 
 
 
 
 
 
 
Figure 2.3 Effect of applying an external RF field (red) of sufficient strength along 
the x axis to induce rotation of the equilibrium magnetization (green) magnetization into 
the transverse plane to –y (dark blue). 
 
The 1D 1H  NMR experiment records the RF emission from the nuclei of 1H atoms only 
and the FID, a concentration of sinusoidal waves (time domain) is Fourier transformed 
to provide a frequency domain spectrum  (figure 2.4).    
 
Figure 2.4 Fourier transformation of a time domain signal to a frequency domain 
spectrum 
 
z 
y 
x 
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This 1D spectrum can be used to provide information as to whether the protein is 
structured.  The x-axis represents the chemical shift, a relative frequency scale expressed 
in parts per million compared to the reference compound tetramethylsilane and figure 
2.5 relates the peaks to different chemical environments. 
 
 
Figure 2.5 1D 1H spectra of unlabelled hMBD1 CXXC1 (10mM deuterated 
tris(hydroxymethyl) aminomethane, 250mM NaCl, pH 6.5)  relating chemical shift (in 
ppm) to different chemical environment. 
 
The 1D 1H experiment can be a powerful diagnostic tool since the sharpness or 
broadness of the peaks relate to how structured the protein/peptide is. Very sharp methyl 
peaks coupled with lack of dispersion (where peaks cannot be distinguished one from 
another) of the backbone amides clustered around 7-8.5ppm can indicate unstructured 
protein.  A structured protein will show good dispersion of peaks (Figure 2.5) in the 
methyl and backbone amide regions.  Broader than expected line widths can be 
indicative of protein aggregation and/or conformational flexibility. 
 
2.2.3 2D Homonuclear 1H NMR 
The 1D 1H experiment is limited in the information it can provide and it is not usually 
possible to assign individual peaks to specific amino acid residues due to overlap.  2D 
homonuclear NMR experiments utilize magnetization transfer between hydrogen nuclei 
that appear as crosspeaks in the spectra.  This correlation of hydrogen nuclei is the basis 
of amino acid assignment and distance restraint measurement.  The simplest 2D 
homonuclear experiment (COSY - Correlation Spectroscopy) takes the preparation and 
Backbone HN 
aromatic Hα 
Side-chain HN 
methyl 
aliphatic 
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detection from a 1D experiment (figure 2.2) and adds an indirect evolution time (T1) and 
mixing sequence (figure 2.6).    
 
 
 
Figure 2.6 Anatomy of a simple 2D homonuclear experiment (COSY). 
 
After preparation, the spins precess for a given time, T1, where the magnetization is 
labelled with the chemical shift of a proton.  The mixing time transfers some of 
magnetization to another proton before detection.  During detection, the magnetization is 
labelled with the chemical shift of the correlated proton.  Magnetization can be 
transferred during the mixing time by scalar coupling for through bond Total Correlation 
Spectroscopy/Correlation Spectroscopy (TOCSY/COSY) or dipolar interactions for 
through space Nuclear Overhauser Effect Spectroscopy (NOESY) experiments.  The 
COSY experiment only transfers magnetization through up to 3 bonds due to the 
weakness of the scalar coupling over greater number of bonds.  Figure 2.7 illustrates the 
connectivities that give rise to cross peaks in TOCSY & NOESY spectra.  A 2D 
homonuclear experiment produces a spectrum with two frequency axes.  Signals for 
each proton detected are recorded along a diagonal, splitting the spectrum into two 
halves.   
 
 
 
 
Figure 2.7 Connectivities that can give rise to cross peaks in A) 1H-TOCSY and B) 
1H-NOESY.  Solid arrows represent intra-residuer transfer, dotted lines represent inter-
residue transfer. 
A B 
                                                                                                                                              46 
A
Bx
x
 
 
 
Figure 2.8 Schematic of a 2D homonuclear spectrum.  Protons A & B are correlated 
by the cross peaks X.  Cross peaks either side of the diagonal result from magnetization 
originating from each proton. The green arrow indicates a cross peak arising from 
magnetization which originated on proton A that was transferred to B. 
 
This diagonal results from magnetization which has not been transferred during the 
mixing time and therefore remains on the same nucleus.  Signals not on the diagonal are 
the result of two protons exchanging magnetization during the mixing time (figure 2.8).      
The cross peaks that correlate a proton to another proton provide information for 
assignment of each cross peak in the spectrum.   
 
2.3 Protein Assignment using 1H homonuclear data 
There are typically three 2D homonuclear experiments, COSY (Correlation 
Spectroscopy), TOCSY (Total Corralation Spectroscopy) and NOESY (Nuclear 
Overhouser Effect Spectroscopy) that can be used for resonance assignment and 
extraction of distance information.  These experiments are used to assign spin systems, 
each of which is a group of resonances representing the chemical shifts of each residues 
protons (amide, alpha and side chain).  As with the 1D 1H spectrum (figure 2.5) specific 
regions within the 2D 1H spectrum correlate transfer between different proton groups.  
Figure 2.9 shows the layout of a 2D 1H spectrum relating chemical shift coordinates to 
proton-proton magnetization transfer. 
δ
1H F1 
δ
1H F2 
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Figure 2.9 Layout of magnetization transfer for a 2D 1H experiment in H2O 
 
2.3.1 Correlation spectroscopy 
The COSY experiment transfers the magnetization by scalar couplings and as such only 
crosspeaks between protons that are up to 3 bonds apart in the spectrum since couplings 
over 3 bonds are too small to be visible.  The COSY experiment is important for 
discriminating β & γ protons for example in glutamate where the chemical shift ranges 
of the β & γ protons overlap.  There would be a COSY cross peak correlating the Hα to 
the Hβ but not to the Hγ. Every amino acid has specific chemical shift ranges for protons 
with in each residue.    
The TOCSY (total correlation spectroscopy) experiment correlates every proton in an 
amino acid residue (figure 2.10) Magnetization is transferred through the entire spin 
system (amino acid) by successive scalar couplings.  As both the TOCSY and COSY 
experiments depend on scalar coupling, they can be used for identifying the chemical 
shift values for the resonances within each spin system.     
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Figure 2.10 Diagram the pattern of crosspeaks for an arbitrary spin system in a 
TOCSY experiment.  Green circles – autocorrelation crosspeaks for the nuclei of the 
spin system, blue circles – cross peaks correlating nuclei.   
 
However, this characteristic pattern (figure 2.11) is shared between certain amino acids 
e.g. cysteine, aspartic acid, phenylalanine, histidine, asparagine, tryptophan and tyrosine 
have the same pattern.  Therefore while it is possible to assign cross peaks to a particular 
spin system it is not possible to assign the spin system to a specific amino acid on the 
basis of the pattern of chemical shifts alone. It is not possible to sequentially link or 
calculate structure based solely on spin system assignments in COSY/TOCSY spectra.  
Assignment of spin systems to sequence specific amino acids requires the spin systems 
to be linked together (see chapter 2.3.3). 
δ
1H  
δ
1H  
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Figure 2.11 Characteristic COSY spectra for each of the 10 classes of amino acid 
residiues and aromatic side chains (reproduced from Smith, 1994)  
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2.3.2 Nuclear Overhauser Effect Spectroscopy  
For structure determination by proton NMR, information about the distance between 
atoms is crucial.  The NOESY (Nuclear Overhauser Effect Spectroscopy) experiment 
relies on dipolar interactions of spins to transfer the magnetization, through space, from 
one nucleus to another.  This through space magnetization transfer allows distance 
information to be obtained for both intra- and inter-residue interactions between protons 
that are typically less than 5Å apart.  The strength of correlation between two nuclei 
depends on the distance between them.  The closer the nuclei are to each other the more 
intense the cross peak in the spectrum.  The NOESY spectrum not only contains cross 
peaks for intra-residue correlation, which are at the same chemical shift coordinates as 
the COSY/TOCSY correlations, but also inter-residue correlations between nuclei close 
in space.  This information is required for linking spin systems together in order to 
assign them sequence specifically. 
  
2.3.3 Sequential Assignment 
Since correlations between nuclei in the same spin system are at the same chemical shift 
in both NOESY and TOSCY/COSY spectra and the Hα to
 
HN i+1 distance is often short 
there is typically an NOE cross peak correlating the Hα
 
from one amino acid and the
 
HN  
the next in sequence.  Figure 2.12 shows an example of backbone sequential linking 
using the Hαi to HN i+1 inter-residue NOE.  It is not possible to rely solely on the Hαi to 
HN i+1 crosspeaks to sequentially link spin systems since there is not always a strong or 
well resolved  Hαi to HN i+1  cross peak.  For example, residues in an alpha helix have 
weak Hαi to HN i+1 but strong HN to HN i+1 NOEs.  Using the known protein sequence it is 
possible to link spin systems using NOE crosspeaks correlating HN and Hβ protons and 
HN and HN resonances of i to i+1 to make the sequential assignment less ambiguous.  
Another problem arises when trying to sequentially link a proline residue since proline 
lacks an amide proton.  Proline residues can normally be sequentially linked using the 
correlation of the proline Hδ and the Hα of the residue before.  Once spin systems have 
been linked sequentially, assignment of the side chain chemical shifts can be completed 
using the COSY experiment to help distinguish side chain protons. 
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Figure 2.12 Example of sequentially linking backbone resonances of hMBD1 CXXC1 
using 2D homonuclear TOCSY (green) & NOESY (blue) spectra by identifying the 
inter-residue 213Arg Hα to
 
214Arg HN crosspeak. 
 
2.3 Heteronuclear NMR  
Atom specific assignment of resonances observed in homonuclear experiments are 
dependant on well resolved spectra.  This can normally be carried out for small globular 
proteins that produce spectra with well dispersed chemical shifts for the protons in each 
of the residues.  Spectra become less well resolved as proteins increase in size due to:  
1) The increase in number of resonances due to the increase in number of protein 
residues while the chemical shift range over which signals are spread does not change.  
This increases the probability of overlap of cross peaks making assignments more 
difficult. 
 2) The decreased rotational correlation time of the protein causing faster relaxation, thus 
increasing overlap due to from broader linewidths.   
The use of 15N labelled protein allows NMR experiments to be carried out which add a 
third (nitrogen) dimension to the spectra.  Separation overlapped 2D crosspeaks possible 
because the spin systems can have different nitrogen chemical shifts (see chapter 4 p81 
for a specific example).  When proteins are labelled with both 13C and 15N, NMR 
experiments can be recorded that transfer magnetization across the peptide bond 
connecting two spin systems though bonds meaning you don’t have to use NOEs to get 
sequential assignment to work.         
1H (PPM) 
1H (PPM) 
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2.3.1 2D 15N-HSQC 
The 15N heteronuclear single quantum correlation (HSQC) experiment correlates the 
nitrogen atom of an NH(x) group to the attached proton.  Thus, the HSQC spectrum 
contains a cross peak for each backbone amide group except proline.  Also visible in an 
HSQC spectrum are the NH2 side chain groups of Asn & Gln, the aromatic NH groups 
of Trp & and more rarely His and the NƐHƐ of Arg (figure 2.13).  
The pulse sequence for a basic HSQC experiment is illustrated in figure 2.14.  The 
INEPT (Insensitive Nuclei Enhanced by Polarization Transfer) pulse sequence is used to 
transfer magnetization from the proton to the nitrogen atom.  A 180º pulse mid evolution 
inverts the proton scalar coupling so that F1 (nitrogen dimension) lineshape does not 
contain contributions from 1H scalar coupling.  A reverse INEPT sequence transfers the 
magnetization back to the proton and detection occurs.  Decoupling the nitrogen channel 
removes the contribution of the nitrogen scalar coupling to the F2 line shape. There is no 
diagonal in the HSQC spectrum because different nuclei are observed during T1 and T2 
 
 
 
 
 
 
δ 
1H  (ppm) 
δ 
15N  
(ppm) 
Figure 2.13 15N HSQC of hMBD1 CXXC1, (Bruker Avance 800 MHz 
with cryoprobe, 10mM deuterated tris(hydroxymethyl)aminomethane,, 
250mM NaCl, pH 7.5, 293K).   
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Figure 2.14 Pulse sequence for a basic HSQC experiment.  Thin bars are 90º & thick 
bars are 180º pulses.  Pulses are applied with x-phases unless indicated above the bar 
 
Although it is not possible to assign cross peaks to specific residues using an HSQC 
alone, the spectrum provides a unique footprint for each protein.  This footprint can 
change depending on buffer conditions and binding to ligands.  This is due to a change 
in the nuclear shielding that the atoms are experiencing, which affects the chemical shift 
at which their resonances are observed at.  This is a useful technique for investigating 
which residues, if assignments are available, interact with an added compound.  Another 
important technique that requires use of the HSQC experiment is hydrogen-deuterium 
exchange for investigating solvent accessibility and hydrogen bonding.  In solution, the 
amide hydrogen in the peptide bonds exchange with the solvent.  When D2O is used as a 
solvent in place of H2O, the amide hydrogen exchange with deuterons.   Since deuterons 
cannot be detected in a 15N HSQC experiment those cross peaks that survive are 
considered to originate from slowly exchanging HN which result from amide protons 
either involved in hydrogen bonds, or burred within a hydrophobic core. 
 
2.3.2 3D 15N heteronuclear NMR experiments 
Ambiguity of sequential resonance assignment in overlapped 2D spectra can be 
generally overcome using 3D heteronuclear versions of 2D homonuclear experiments.  
These experiments combine a 2D homonuclear TOCSY or NOESY pulse sequence and 
an HSQC pulse sequence.  For an HSQC-NOESY experiment the pulse sequence 
(Figure 2.15) starts with a homonuclear NOESY with a 90º pulse to switch 
magnetization to the transverse plane, a variable evolution time t1 to provide chemical 
shift information in the F1 domain then another 90º pulse to move the magnetization 
back to the z-axis with magnetization transfer through dipolar coupling during the 
mixing time Tm.  The remainder of the pulse sequence is identical to the HSQC 
experiment described above.       
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Figure 2.15 Pulse sequence for a 3D 1H-15N HSQC-NOESY experiment. Thin bars 
are 90º & thick bars are 180º pulses.  Pulses are applied with x-phases unless indicated 
above the bar.  
 
The advantage of introducing the 3rd dimension in a 15N HSQC-NOESY or –TOCSY 
experiment is that since only cross peaks linked to an NH are seen in each slice, 
overlapped peaks can normally be separated by their 15N chemical shift (figure 2.16). 
 
 
Figure 2.16 Illustration showing the relationship between a 2D homonuclear spectrum 
and a 3D heteronuclear spectrum.  The overlapped cross peaks in the 2D spectrum 
(green) are separated by the introduction of the nitrogen dimension (F3).  
 
 
 
                                                                                                                                              55 
2.4 Data Processing 
Before resonance assignment can begin, the recorded NMR data has to be processed 
from the time domain to the frequency domain.  Normally the direct Fourier 
transformation (DFT) of the recorded NMR signal does not yield an optimal spectrum.  
In order to maximize the information that can be extracted from the spectrum a number 
of digital signal processing techniques can be applied before and after Fourier 
transformation.  
 
2.4.1 Pre-Fourier transformation data processing 
A DFT of the FID recorded by the NMR spectrometer produces a frequency domain 
signal with a Lorentzian line shape.  The shape of the line can be improved to give 
greater resolution and sensitivity by applying functions to the FID before DFT. The 
Lorentzian line shape is produced from an FID that decays exponentially.  Therefore, if 
the decay of the FID is altered to decay with a different time dependence the resolution 
and/or single to noise can be adjusted.  Multiplying the FID by exponential function will 
deemphasize the later parts of the FID where the signal from the protein is weakest.  The 
Lorentzian-to-Gaussian is a common function applied to the FID.  The Lorentzian lines 
are converted to Gaussian lines by multiplying by an increasing exponential followed by 
a Gaussian function.  Figure 2.17 shows the effect of applying the Gaussian function to 
the FID. 
 
    
 
Figure 2.17 Diagram of the effect on line shape for a Lorentzian-to-Gaussion 
transformation.  Line width at half height are the same. (Adapted from James Keeler 
lecture notes University of Cambridge, http://www-
keeler.ch.cam.ac.uk/lectures/understanding/chapter_4.pdf) 
 
Lorentzian 
Gaussian 
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A function similar to the Gaussian is the sine bell function.  There is also a squared sine 
bell function which is more concentrated around the maximum.  Figure 2.18A illustrates 
the difference between sine bell and squared sine bell and figure 2.18B illustrates the 
flexibility of the (squared) sine bell function.  The squared sine bell function is good to 
use because it goes smoothly to zero which produces fewer truncation artifacts compared 
to the sine bell function. 
 
 
Figure 2.18  comparison of sine bell & squared sine bell curves (A) Flexibility of the 
squared sine bell function by applying a phase shift (B).  (Adapted from James Keeler 
lecture notes, University of Cambridge, http://www-
keeler.ch.cam.ac.uk/lectures/understanding/chapter_4.pdf) 
 
 For each NMR experiment a sweep width is set which is the range over which the data 
is collected (set in ppm or Hz).  To obtain a high digital resolution it is necessary to 
record a large number of data points in this sweep width (Hz/data points).  The noise in 
an FID remains more or less constant whereas the signal sinusoids decay over time.  
Therefore, at some point noise contributes more to the FID than the nuclear resonances.  
It is possible to record a smaller number of points and then extrapolate the FID by 
process called zero-filling if the signal has decayed by the end point.  Zero-filling simply 
adds zeros to the data sequence.  If the signal has not decayed when recording stops the 
FID is truncated and zero-filling leads to oscillations around the base of the peak called 
sinc-wiggles (the name comes from the peak shape as it is related to a sinc function). 
(figure 2.19).   
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These sinc-wiggles can cause problems during resonance assignment later on.   
 
 
 
 
 
Figure 2.19 Figure illustrating the effects of truncation of the FID on the 
corresponding spectrum.  For spectrum A the FID was allowed to decay to almost zero 
where as spectrum B shows sinc wiggle artifacts caused by truncation of the FID. 
(Adapted from James Keeler lecture notes, University of Cambridge, http://www-
keeler.ch.cam.ac.uk/lectures/understanding/chapter_4.pdf) 
 
2.4.2 Post-Fourier transformation data processing 
After DFT the spectrum normally displays a phase error.  This is because the time-
domain signal is a complex signal as the sum of sine and cosine functions.  The DFT of 
this complex time domain results in a frequency domain comprising of real part 
(absorption) and an imaginary part (dispersion), shown in figure 2.20, which are out of 
phase. This results in their full width of the peak at half maximum no longer being the 
same for each part. 
 
 
 
 
A B 
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Figure 2.20 illustration showing the real (absorption) and imaginary part (dispersion) 
of a Lorentzian. 
 
 
Applying zero-order (frequency independent) correction will correct phasing at the 
chosen pivot point.  To correct remaining phase errors away from the pivot point, first 
order (frequency dependent) correction is applied.  A curved or rolling baseline makes it 
more difficult to pick peaks in a spectrum and is also a source of error in quantification. 
Baseline distortions are mainly caused by the corruption of the first few data points of an 
FID. Baseline correction methods fall into two categories, time domain correction 
methods that reconstruct the corrupted data points in the FID and frequency domain 
correction methods that construct baseline curves to fit the spectra directly then subtract 
these baseline curves to remove the distortion.  After adjusting the processing 
parameters to produce a well resolved spectrum, the data can be loaded into various 
programs for resonance assignment and production of NMR distance constraints (See 
chapter 4) 
   
2.5 Alternative to DFT processing 
Processing using Fourier transformation is a fast way of producing a frequency domain 
spectrum from a recorded FID.  The DFT, as shown above, introduces oscillation 
artifacts when the FID is truncated.  If strong window functions are applied to reduce 
these artifacts there is a reduction in resolution.  In the case of 3D NMR experiments 
where the indirect detected dimensions are truncated due to time constraints, various 
methods have been developed to overcome this problem.  For example, maximum 
entropy reconstruction (Sibisi et al, 1984), linear prediction (Barkhuijsen et al, 1985), 
maximum likelihood (Hoffman et al, 1989) and Multi-Dimensional Decomposition 
(Orekhov et al, 2003) .  Processing of the 3D data in this thesis was carried out using the 
maximum entropy reconstruction method. The maximum entropy reconstruction method 
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creates a trial frequency domain spectrum then inverse FT back to an FID to compare 
with the FID recorded on the spectrometer.  The software then adjusts the simulated 
frequency domain spectrum until the inverse FT matches the recorded FID.  The inverse 
FT will never exactly match the recorded FID since the simulated frequency domain is 
devoid of noise.  Noise can be introduced to the simulated frequency domain spectrum 
so that the inverse FT will match the recorded FID more closely.  Using maximum 
entropy reconstruction on truncated data will normally produce a frequency domain 
spectrum with improved resolution compared to the Fourier transformation spectrum.  
However, maximum entropy reconstruction does not produce spectra that are as resolved 
and distortion free as the Fourier transformation of an untruncated FID.      
 
2.6 important considerations for recording NMR spectra 
Recording NMR spectra is not as simple as putting a protein sample in a tube and 
placing it in the NMR machine.  Various characteristics of the protein have to be taken 
into account in order to prolong the life of the sample enough to record the required data.  
Not only are conditions that suit the protein important but also conditions that result in 
good spectra. 
 
2.6.1 Temperature, pH and Salt 
Protein samples should be kept at the lowest temperature possible in order to prolong the 
life of the sample.  However, low temperatures are generally not suited to recording 
NMR spectra due to slower molecular tumbling, which leads to broader lines and lower 
sensitivity.  However, high temperatures can also increase the rate of exchange with 
water and broaden the line widths due to increased dynamics and will ultimately cause 
the denaturation of the protein.  Therefore a temperature must be chosen to give the best 
overall compromise of resolution and sample life.  Figure 2.21 shows the effect of 
temperature on the xDNMT1 CXXC domain in 5K steps from 283 K to 303K.  As we 
increase temperature, the resolution increases as lines narrow around the 8.75 to 9.5 ppm 
region.  The spectrum at 293K appears to present the best overall compromise conditions 
for adequate resolution.   
The optimum pH for protein NMR is pH 4.0-4.5 since amide proton exchange with 
water is slowest at this pH.  As you move away from this range, amide exchange 
increases which can result in fewer amide protons being visible.  This can be seen in the 
15N spectra of hMBD1 CXXC1 where NH of histidine 200 is not visible (p ).  However 
not all proteins are stable at low pH, or their catalytic activity may be altered due to 
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altered protonation states of the active site residues. 
Sodium chloride is an important constituent of many protein chemistry buffers as it can 
prevent the protein from precipitating.  This prevention of precipitation may be due to  
solvent counter-ions migrating towards the protein resulting in a layer which repulses the 
co-ions left in solution.  However, as you increase NaCl concentration the conductivity 
of the solution also increases.  The increase in conductivity not only affects the effective 
radio frequency power felt by the sample but also by the receiver coils of the 
spectrometer used to record the RF signal.  Thus sensitivity is reduced.  The reduction in 
effective RF power can be partially corrected by increasing pulse width, but this results 
in pulses that are further from ideal with various consequences for the quality of the 
resulting spectrum. 
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Figure 2.21 1D 1H spectra of unlabelled xDNMT1 CXXCb (10mM deuterated tris 
(hydroxymethyl)aminomethane, 250mM NaCl, pH 7.0) at various temperatures.  Water 
suppression using the method of Hwang and Shaka (1995) 
 
 
283K 
288K 
293K 
298K 
303K 
                                                                                                                                              62 
2.6.2 Protein size 
In solution NMR, amide 1H from any unstructured regions of a protein will appear in the 
7-8.5 ppm region of a 1D 1H spectrum, resulting in a decrease in peak dispersion and 
increase in the overlap of the cross peaks in the spectra.  Shortening of the domain at the 
N- and C- termini can have a pronounced effect on the spectra recorded since the termini 
of protein domains are often unstructured.  In the case of xDNMT1 CXXC domain, 
shortening the construct from both termini had a dramatic effect on the resolution of the 
recorded spectra.  Figure 2.22 shows the differences between the three constructs 
 
  CXXCa 506FFSEQIEKDAE                      DEDEEVEDVLPEMPSPKKILQGKKKKLE600 
  CXXCb                               517                   DEDEEVEDVLPE584 
  CXXCc            517                           572 
 
      
517 KENGIKRRRCGVCEVCQQPDCGQCKACQAMLKFGGAGRTKQACM 
       QRRCPNLAVKEA572  
 
Figure 2.22 Schematic showing the amino acid sequences of the three xDNMT1 
CXXC constructs.  The green box represents xDNMT1 CXXCc whose sequence is 
shown below 
 
NMR spectra for the three xDNMT1 CXXC constructs shown above are shown in figure 
2.23.  Both CXXCb and CXXCc show less peak overlap in the 7-8.5 ppm region when 
compared to CXXCa, with the 8.5 – 9.5 ppm region becoming better resolved as the size 
of the construct becomes smaller.  The peak around 0.6 ppm also becomes more intense 
relative to other peaks in the aliphatic region as the domain is shortened (this peak 
disappears when the protein is unstructured e.g. upon addition of EDTA to the sample).   
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Figure 2.23 1D 1H spectra of unlabelled various xDNMT1 CXXC contructs (10mM 
deuterated tris (hydroxymethyl) aminomethane, 250mM NaCl, pH 7.0) Water 
suppression using the method of Hwang and Shaka (1995).  
 
 
 
 
 
 
xDNMT1 CXXCa 
xDNMT1 CXXCb 
xDNMT1 CXXCc 
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CHAPTER THREE 
 
SAMPLE PREPARATION & NMR SPECTROSCOPY of hMBD1 CXXC1 
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3.1 Cloning of hMBD1 CXXC1 Domain 
This section describes the strategy used to design hMBD1 CXXC1 constructs, to express 
and purify the hMBD1 CXXC1.  The NMR experiments carried out are also described. 
 
3.1.1 Bacterial transformations 
All bacteria used were chemically competent.  Heat shock was therefore used to 
transform the DNA into the cells.  The bacteria were removed from –80˚C and 
immediately placed on ice to defrost before 1 µl (mini prep DNA) or 1.5 µl (DNA 
ligation) was added and gently stirred with the pipette tip.  The bacteria were incubated 
on ice for 2 minutes before being heat shocked at 42˚C for 30 seconds and then placed 
back on ice for a further 5 minutes.  300 µl 37˚C pre-warmed SOC media was added 
before the bacteria were incubated at 37˚C & 200 rpm for 1 hour.  For plasmid 
transformations 50, or  for ligations 350 µl of culture was spread onto pre-dried LB-agar 
containing the required selection antibiotics.  The culture was allowed to dry into the 
LB-agar (approximately 15 minutes) before being placed in a 37˚C incubator overnight.  
Single colonies could then be picked the next day for inoculation into LB for plasmid 
purification or protein expression. 
 
3.1.2 Agarose Gel Electrophoresis 
1 gram of multiple purpose agarose (Roche, Cat No. 1388991) was put into a 250 ml 
conical flask containing 100 ml TBE buffer.   The agarose was dissolved by heating in a 
900 W microwave for approx 90 s.  Ethidium bromide was added to the agarose to a 
final concentration of 10 µg/ml once it had cooled to approximately 50˚C.  It was then 
poured into the casting tray of the electrophoresis apparatus (BioRad, Cat No. 164-0310) 
containing a sample comb and allowed to solidify at room temperature.  Once the gel 
had set the comb was removed carefully and TBE buffer added to the tank in order to 
cover the gel by approx 5-6 mm.  DNA samples were mixed with 6x loading buffer 
(Promega, Cat No. G1881) then pipetted into the wells.  NEB 2-log ladder (Cat. No. 
N3200S) was added for size referencing before electrophoresis was carried out under 
conditions of constant voltage at 100V for as long as it was required to separate each 
specific sample (30-60 minutes).  Migration of the DNA was detected by fluorescence of 
ethidium bromide bound to DNA under UV illumination 
 
3.1.3 Considerations when choosing domain size to express 
When studying a protein in solution, non-structured areas of a protein are more flexible 
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than the structured domains.  The flexible unstructured regions will tend to have no long 
range NOEs and when present at the N & C termini of a protein will not contribute any 
information to the overall structure of the protein.  Flexible N- & C- termini will also 
give rise to additional poorly resolved cross peaks in the NMR spectra making 
assignment more difficult.  Thus, it is important to express a domain with minimal N- & 
C-terminal overhangs if possible. 
 
3.1.4 PCR of hMBD1 CXXC1 Domain 
Using the sequence identified by Cross et al (1997) a BLAST search revealed an 
IMAGE clone that contained the cDNA required to amplify the hMBD1 CXXC1 
domain.  The clone containing the DNA sequence of interest, GENBANK accession 
number CF552871, was purchased from Geneservice Ltd (clone ID 30529682).  The 
cDNA had been cloned into pCMV SPORT (ampicillinR) which was transformed into 
chemically competent DH5α E.coli cells (Invitrogen, Cat No.18265-017).  A stock of 
plasmid was prepared by inoculating a single colony into 10 ml of Lauria Broth (LB) + 
100 µg LB and grown overnight at 37ºC in an orbital incubator at 200 rpm.  Plasmids 
were purified by alkali-lysis using a GenEluteTM plasmid mini prep kit (Promega, Cat 
No PLN-350).  PCR primers were designed based on the solution structure of the MLL 
CXXC domain (Allen et al, 2006) in order to minimize flexible non-structured N- & C- 
termini.  Allen et al assigned and calculated the structure for residues V1146 to K1214 
of the MLL CXXC domain but found that only residues R1150-P1201 adopted a well-
defined tertiary structure.  Based on their structure primers were designed to amplify the 
region from MBD1 encoding amino acids 166-222, to give the least amount of flexible 
N- & C- termini (figure 3.1).  The gene fragment was cloned into a pGEX-6P1 (GE 
healthcare, Cat No. 27-4597-01) expression vector containing an N-terminal PreScission 
protease site (Figure 3.2).  PreScission protease is a fusion protein of glutathione S-
transferase and human rhinovirus type 14 3C protease (Habig et al, 1974) allowing a one 
step cleavage/protein elution step when using a GST-resin for purification.   
 
 
Figure 3.1 Amino acid alignment of CXXC domains from MLL and hMBD1 
comparing the sequence used by Allen et al and the domain cloned for this study 
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Figure 3.2 Plasmid map and multiple cloning site of pGEX-6P1 showing the 
PreScission protease cleavage site (GST handbook, GE healthcare). 
 
The PCR primers (figure 3.3) included restriction sites to clone the PCR product into 
pGEX-6P1 so that the CXXC domain would be expressed in frame with the GST tag.    
 
hMBD1 CXXC1 fwd  5’ GGGATCCGAGCAGAGAATGTTTAAG 3’ 
hMBD1 CXXC1 rev 5’ CTCGAGTCAGCTCCTTTCCACAATC 3’  
 
Figure 3.3 Primers for the PCR amplification of hMBD1 CXXC1 domain.  The 
restriction sites used (fwd BamH1, rev Xho 1) are shown in bold with the stop codon 
underlined 
 
PCR primers were ordered from Sigma Genosys and diluted to a stock concentration of 
100 µM.  Amplification was carried out on a Techne TC-512 thermo cycler using 
PfuTurbo® DNA polymerase (Stratagene, Cat No. 600250) with the IMAGE clone 
30529682 as a template.  The DNA template was diluted 1:100 from a plasmid mini prep 
stock. PCR reaction mix was as follows: 
 
1 µl (0.5µg) DNA template 
1 µl of each primer (50µM stock) 
1 µl of dNTP mix (NEB, Cat No N0447S) 
0.5 µl (1.25 units) Pfu Turbo DNA polymerase 
5 µl 5x Pfu Turbo DNA polymerase buffer 
41.5 µl ultrapure water 
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35 cycles 
MBD1 CXXC1 
PCR 
As PfuTurbo is not a hotstart enzyme, it was added to the reaction after the initial 5 
minutes at 95ºC followed by  
1min 95ºC 
1min 60ºC 
1min 72ºC 
With a final extension of 10 mins at 72ºC producing a product 183bp long.   
 
To purify the DNA, the sample was subjected to agarose gel electrophoresis.  The PCR 
reaction was mixed with loading buffer (Promega, Cat No. G1881) and run on a 1% 
agarose gel (Roche, CAT No 1388991) prestained with 5µl ethidium bromide (stock 
10mg/ml) alongside 2-log DNA marker (NEB, Cat No N3200S) (fig 3.4).  The DNA 
was visualized by detection of ethidium bromide fluorescence upon exposure to ultra 
violet light and excised from the gel.  The DNA was purified from the gel slice using a 
QIAquick gel extraction kit (Qiagen, Cat No 28704) according to the manufacturer’s 
instructions and eluted in 30µl. 
 
 
 
Figure 3.4  Agarose gel electrophoresis negative image of the MBD1 CXXC1 PCR 
product.  M - 2-log DNA marker 
 
3.1.5 Cloning of PCR product into pGEM-T easy 
In order to clone the cDNA fragment into the pGEM-T easy vector (Promega, Cat No 
1360) adenine overhangs (A-tail) had to be created since Pfu Turbo is a proof reading 
enzyme and removes any overhangs.  Taq polymerase (NEB, Cat No M0273S) was used 
in the following reaction to add the A-tail to the PCR fragment.  The reaction was 
incubated for 15 mins at 72ºC. 
 
 
 
M 
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1 µl (5 units) Taq DNA polymerase 
1 µl dATP 4mM stock (Promega, Cat No. U1201) 
1 µl 10x Taq polymerase buffer 
7 µl gel purified DNA 
 
The A-tailed DNA was then cloned into pGEM-T easy according to the manufacturer’s 
instructions and transformed into chemically competent DH5α cells.  Positive clones 
were identified using blue/white selection (see appendix), inoculated into 10 ml LB + 
100 µg/ml ampicillin and grown overnight at 37ºC in an orbital incubator at 200 rpm.  
Plasmids were purified by alkali-lysis as described above.   Cloning into pGEM-T easy 
allowed the digestion of the construct with BamH1 (NEB, Cat No R0136S) & Xho1 
(Promega, Cat No R6161) to release the MBD1 CXXC1 fragment with sticky ends 
enabling ligation into pGEX-6P1.   pGEX-6P1 was digested with the same enzymes; the 
fragments were then separated by agarose gel electrophoresis and then excised from the 
gel (Fig. 3.5).   The restriction digest which included the following 
 
34µl DNA from standard mini prep elution 
4µl NEB BamH1 buffer 
1µl BSA (10mg/ml stock concentration) 
1µl of BamH1 (20 units) & Xho1 (10 units) enzymes 
 
was incubated for 90 minutes at 37ºC 
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3.1.6 Cloning of MBD1 CXXC1 into pGEX-6P1 
The MBD1 CXXC1 insert and pGEX-6P1 were ligated using NEB T4 Ligase (Cat No 
M202S) according to the manufacturer’s instructions, transformed into DH5α cells and 
spread onto LB agar plates containing 100 µg/ml ampicillin and grown overnight at 
37ºC.  Colonies were inoculated into 10 ml LB + 100 µg/ml ampicillin and grown 
overnight at 37ºC in an orbital incubator at 200rpm.  Plasmids were purified from the 
bacteria using alkali-lysis as described above and digested with restriction enzymes 
BamH1 & Xho1 to identify clones containing an insert of the expected size (fig 3.6).  
Correct clones were sent to Cogenics for sequencing.  Clones with the correct sequence 
were used for protein expression 
 
 
 
V I 
CXXC1 Fragment 
M1 M2 
Figure 3.5 Agarose gel electrophoresis of the digested pGEX-6P1 vector and  
pGEM-T CXXC1 construct. M1 1KB ladder NEB, M2 100bp ladder NEB V – pGEX-
6P1, I – pGEM-T CXXC1 
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 1           2           3            4          5           6          7           8 
 
 
Figure 3.6 Agarose gel electrophoresis of a selection of 8 putative pGEX6P1-
hMBD1CXXC1 clones digested with BamH1 and Xho1. The arrow 
indicates the expected position of the CXXC1 fragment. Clones 2, 5, 6 & 
8 show the expected fragment pattern.  M- NEB 2-log ladder. 
 
3.2 Protein Sample preparation 
The pGEX-6P1 system utilizes a GST (Glutathione S-Transferase) tag for purification of 
the target protein on a Glutathione sepharoseTM 4 fastflow resin (GE healthcare, Cat No. 
17-5132-01).  Cleavage of the GST tag from the target protein was achieved using 
PreScission Protease (GE Healthcare, Cat No. 27-0843-01). 
 
3.2.1 Expression of the hMBD1 CXXC1 domain 
Based on previous experience with the CXXC domain from xDNMT1 and the 
publication of the MLL CXXC structure (Allen et al, 2006) pGEX-6P1 CXXC1 was 
transformed into chemically competent TunerTM DE3 cells genotype F– ompT hsdSB (rB– 
mB
–) gal dcm lacY1 (Novagen, Cat No 70623-4), spread onto LB plates containing 100 
µg/ml ampicillin and grown overnight at 37ºC.  Single colonies were inoculated into 50 
ml of LB containing 100 µg/ml ampicillin in a 250 ml conical flask then incubated 
overnight.   
 
The 50 ml cultures were pelleted by centrifugation at 4300 g for 5 mins at 5000 rpm.  
The supernatant was removed and the pellet resuspended in 5 ml LB which was used to 
inoculate 500 ml of LB containing 100 µg/ml ampicillin in a 2 L conical flask.  The 
bacteria were grown at 37ºC in an orbital shaker, 200 rpm, to an OD600 between 0.6-0.8 
before being cooled to 4ºC.  Protein expression was induced by the addition of 150 µl of 
IPTG (1 M stock) to give a final concentration of 300 µM.  The bacteria were placed 
back in the orbital incubator to express overnight at 13ºC.  For isotopically labelled 
M 
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protein, the bacteria were grown in 500 ml of M9 minimal media rather than LB.   
 
3.2.2 Purification of hMBD1 CXXC1 domain 
A typical preparation of 4-5 mg of protein required 2 L of bacteria grown in 4x500 ml 
lots.  The bacteria were pelleted by centrifugation for 10 minutes at 4300 g.  The 
supernatant was removed and the bacteria resuspended in phosphate buffered saline 
solution (PBS) pH 7.3 (10 ml per 1 L of culture) then frozen at -20ºC.  To lyse the cells, 
they were first defrosted and warmed to room temperature (RT) before 2 ml of 10x 
BugBusterTM (Novagen, Cat No 70921-5) and 125 units of benzonase® nuclease 
(Novagen, Cat No 70746-3) were added.  The sample was incubated on a roller mixer 
for 20 mins at room temperature (RT).  Soluble and insoluble material was separated by 
centrifugation for 25 mins at 19872 g.   An empty econo-pac column (Bio-Rad, Cat No 
732-1010) was filled with a 3 ml bed volume of FastFlowtm 4 glutathione sepharose and 
equilibrated by washing the resin with 5 bed volumes of PBS pH 7.3.  The supernatant 
was passed through the resin twice which was then washed with 5 bed volumes of PBS 
pH 7.3.  To remove the tag, 80 units of dialysed PreScission was mixed with 3 ml of 
PreScission protease buffer minus EDTA.  To remove EDTA from the PreScission 
protease it was dialysed against 1L 50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 1 mM 
DTT using a Thermo Scientific Slide-A-Lyzer Dialysis Cassette 7000MWCO (Cat. No. 
66373).  Glycerol was added to the dialysed sample to a final concentration of 20%.  The 
PreScission protease was aliquoted and stored at –20˚CThis was then added to the 
column and the resin gently resuspended before being incubated at 4ºC overnight.  The 
cleaved MBD1 CXXC1 domain was eluted from the column by applying 20 ml of 
elution buffer (see appendix).  Samples of the soluble lysis fraction, the flow through, 
the resin and the elution were analysed by SDS-PAGE (Figure 3.7).  The samples were 
mixed with 4X NuPAGE LDS sample buffer (Invitrogen, Cat No. NP0007) prior to 
being loaded into pre-cast NuPAGE 4~12% bis-tris gels (Invitrogen, Cat No. 
NP0321BOX). The samples were heated to 85 0C for 10 min with 90 mM β-
Mercaptoethanol before loading. Protein markers (BioRad, Cat No. 161-0373) were 
diluted with two volumes of water and one volume of NuPAGE LDS sample buffer and 
10 µl was loaded. The gel was run at 200 V constant voltage for 35 minutes. The protein 
bands were visualized after staining the gel with approximately 100 ml of coomassie 
stain for 5 to15 min followed by destaining in 100 ml of destaining buffer overnight at 
room temperature 
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Using the conditions described above for expression and purification of the protein 
resulted in an approximate yield of 4-5 mg of purified soluble protein when measured by 
Bradford assay which could be concentrated and buffer exchanged (chapter 3.2.3).       
 
 
Figure 3.7 SDS-PAGE analysis of the expression and purification of MBD1 CXXC1 
domain expressed in TunerTM DE3 cells. The image has been edited to place lanes F, R 
and E together since they were spaced out on the original gel.    
 
3.2.3 Sample concentration and buffer exchange 
For NMR spectra to be recorded within a sensible time, the protein concentration within 
the NMR sample must be at least 0.5 mM.  Since experiments can take place at 
temperatures which make the protein more liable to go off (precipitation, protease 
digestion, unfolding) the shorter the experimental time taken the better.  More 
concentrated samples produce better signal to noise enabling this.  Using a vivaspin20 
5kDa molecular weight cut off spin concentrator (Sartorius Stedim, Cat No VS2012) it is 
possible to both buffer exchange and concentrate the sample to the appropriate volume 
(500 µl).  The concentrator was washed with water to remove the glycerol preservative 
before addition of the eluted protein.  The sample was concentrated to 500 µl by 
centrifugation at 3056 g and 10ºC.  NMR buffer was added slowly to a total volume of 
20 ml and the process repeated twice achieving a 1600 fold dilution of the original 
buffer.  The purification of MBD1 CXXC1 resulted in NMR samples of between 1-
1.25mM 
M S F R E 
M – Biorad prestained molecular weight 
marker 
S – 20 µl soluble lysis fraction 
F – 20 µl flow through fraction 
R – 20 µl of resin after washing 
E – 10 µl of eluted MBD1 CXXC1 protein 
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The concentrated sample was centrifuged at 13000 rpm for 5mins in a bench top 
microcentrifuge to remove any particles before 30 µl of D2O was added.  D2O provides a 
deuterium lock signal for the NMR spectrometer.   The sample was made up to 600 µl 
with ultrapure water before being gently pipetted into an NMR tube (Wilmad 535-pp or 
Novell S607)   
 
3.3 NMR spectroscopy  
Data was recorded on Bruker AVANCE 600 MHz & 800MHz NMR spectrometers, 
equipped with 5 mm TCI cryoprobes.  NMR experiments were carried out using 1 mM 
protein samples except for DNA titration (100 µM).  The experiments carried out are 
shown in table 3.1.  1D and 2D NOESY, TOSCY experiments unlabelled protein was 
used.  For COSY (and another 2D NOESY) experiment, NMR buffer was made with 
D20 in place H20.  3D TOCSY-HSQC and NOESY-HSQC, 15N labelled protein was 
expressed using M9 minimal media supplemented with 15N labelled ammonium 
chloride.  All experiments were carried out at a temperature of 293 K. 
 
3.3.1 DNA Titration of hMBD1 CXXC1 
A Palindromic DNA oligonucleotide of 12 bp length (12mer -GCTTACGTAAGC ) was 
purchased from Sigma Genosys (reverse phase HPLC purified).  The oligo was 
resuspended in nuclease free water (promega) to a concentration of 84 uM per ml.  
Annealing of the oligo was performed by heating the sample to 95˚C then allowing it to 
cool slowly to room temperature.  The 12mer was then aliquoted into 600 µl (50 µM) 
samples before being lyophilized.  This allowed the DNA to be mixed with the NMR 
sample without decreasing the concentration of the NMR sample.  An HSQC was 
carried out at protein:DNA concentration ratios 1:0, 1:0.5, 1:1, 1:3 to investigate the 
DNA binding ability of the hMBD1 CXXC domain 
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  Dimension 1   Dimension 2   Dimension 3     
Experiment Nuc TD SW Nuc TD SW Nuc TD SW RD 
ms 
NS WS 
100ms 
NOSEY 
1H 2048 8503 1H 2048 7001    1.0 32 ES 
200ms 
NOSEY 
1H 2048 8503 1H 2048 7001    1.0 32 ES 
100ms 
NOSEY* 
1H 2048 9615 1H 1024 9596    1.0 32 ES 
60 ms D2O 
NOSEY 
1H 2048 8503 1H 2048 7000    1.0 16 PS 
60 ms 
TOCSY 
1H 2048 8503 1H 2048 7001    1.0 32 ES 
COSY 1H 2048 8503 1H 2048 7001    1.0 32 WG 
D2O COSY 1H 2048 8503 1H 2048 6999    1.0 24  
HSQC* 1H 2048 12820 15N 128 1702    1.0 8 WG 
HSQC + 
DNA 
1H 2048 9615 15N 128 1277    1.0 32 WG 
HSQC-
NOSEY* 
1H 1024 11160 1H 512 11160 15N 128 1702 1.0 8 WG 
HSQC-
TOCSY* 
1H 1024 11160 1H 256 11160 15N 128 1702 1.0 8 WG 
 
Table 3.1 Acquisition parameters of NMR experiments (Bruker AVANCE 600 MHz unless * then Bruker AVANCE 800 MHz) used for resonance 
assignment and structural restraints collection. Nuc: Nucleus, TD: time domain points (complex), SW: sweep width in Hz, RD: relaxation delay, NS: 
number of scans, WS: water suppression, WG: water gate, ES: excitation sculpting, PS: presaturation, ms: milliseconds,  
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CHAPTER FOUR 
 
 
CHEMICAL SHIFT ASSIGNMENT AND STRUCTURE CALCULATION OF 
hMBD1 CXXC1 
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4.1 NMR protein structure calculation 
This chapter shows how the chemical shifts of the resonances of hMBD1 CXXC were 
assigned using CcpNMR analysis software (Vranken et al, 2005), how distance 
restraints were derived from NOESY spectra and how ARIA (Ambiguous Restraints for 
Iterative Assignment) was used for structure calculations.    
 
4.2 Is the protein is structured? 
NMR experiments used to generate spectra for chemical shift assignment and to 
calculate NOE distance restraints takes significant time to complete.  Before such 
experiments are undertaken the sample must be checked to evaluate whether it is 
structured.  For an unlabeled sample, the observation of particular features in a 1D 1H 
spectrum is normally sufficient to suggest that a sample is structured.  The 1D 1H 
spectrum of unlabeled hMBD1 CXXC1 (figure 4.1) suggests that the protein sample is 
folded due to the overall dispersion of chemical shifts in the methyl (0-2ppm) and amide 
(8.5-10ppm) regions and the 1H line widths.    The 1D 1H experiment is relatively short, 
typically 8 seconds for a 0.5mM hMBD1 CXXC1 sample, therefore it is ideal to run, to 
be sure the sample has not unfolded or precipitated, between the longer 2D TOCSY, 
NOESY, COSY experiments. 
 
For larger proteins, >10kDa, the 1D 1H NMR experiment is not ideal due to potential 
overlap of chemical shifts and broader line widths.  In these situations isotopically 
labeled proteins are required due to increasing overlap in homonuclear 2-D spectra.    
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4.3 Sequence specific resonance assignment of hMBD1 CXXC1  
The relatively small size of the CXXC domain lends itself to structural determination 
though homonuclear NMR, thus not incurring the high cost associated with 13C & 15N 
labeling or problems of achieving sufficient quantity of protein from growth in M9 
minimal media. Sequence specific resonance assignment of hMBD1 CXXC1 was 
attempted using 2D NOESY & TOCSY spectra according to the method described by 
Wutrich et al, and although significant stretches of amino acids could be assigned, 
crucially the remaining resonances could not be assigned due to features of the spectrum 
as set out below.    
 
4.3.1 Overlapping regions make sequential assignment difficult 
The TOCSY and NOESY spectra for hMBD1 CXXC1 are mainly well dispersed except 
for a part for the Hα-HN correlation region where there is significant overlap (figure 4.2).  
This region, centered around 4.3, 8.3 ppm proved problematic for sequential assignment 
of the backbone HN to Hα atoms.  An example of the difficultly in assigning crosspeaks 
in overlapped spectra is shown in figure 4.3. Figure 4.3 shows the TOCSY Hα-HN and 
aliphatic-HN crosspeaks for arginines 169 & 173.  Arginines 169 & 173 share the same 
HN chemical shift which makes it difficult to distinguish which cross peak belongs to 
which amino acid.  It was also not possible to assign sidechain cross peaks to either of 
these arginines.   
 
Not only did it prove difficult to assign certain amino acids using only 2D spectra but it 
was also difficult to sequentially assign spin systems.  As previously described in 
chapter two (p49) side chains have characteristic crosspeak pattern and chemical shift 
patterns which allow spin systems to be assigned to an amino acid type.  This allows 
spins systems to be labelled as e.g. a cysteine or glycine without assigning it in 
sequence.  For example, the amino acid sequence of hMBD1 CXXC1 contains only one 
histidine. Therefore it was possible to identify which crosspeaks belonged to histidine 
200.  However, using only 2D homonuclear NOESY & TOCSY spectra is was not 
possible to assign the adjacent residues 199 and 201.           
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δ
 1H (ppm) 
 
1H (ppm) 
δ
 1H (ppm)  
 
 
 
Figure 4.3 TOCSY strips for the partially assigned arginine 169 & 173 residues.  
Annotated with assignments made using 15N labelled protein   
 
4.3.2 Assignment of phenylalanine side chains 
Using D2O rather than H2O as the NMR sample solvent means the HN are replaced by a 
deuteron due to proton exchange with the solvent.  The DN no longer produces a 1H 
NMR signal and therefore there are no cross peaks in the HN region of the spectrum.  
However the cross peaks from aromatic sidechains remain visible (figure 4.4).  Of the 3 
types of aromatic protons in phenylalanine, only Hδ is expected to give strong NOESY 
cross peaks to Hα or Hβ, with Hε and Hζ showing weaker signals.  hMBD1 CXXC1 
only contains two phenylalanines.  Thus, with the sequence specific assignment of P207 
from C208 this allowed for the rapid assignment of P207 sidechain.  The remaining 
crosspeaks were therefore where assigned to P171.       
a) Hα- HN chemical shift region b) Aliphatic-HN chemical shift 
region 
δ
 1H 
(ppm) 
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Figure 4.4 Strips for the NOESY of hMBD1 CXXC1 recorded in D20 showing cross 
peaks of 171F & 207F.  A, D2O NOESY only (aqua) B, D2O NOESY overlaid with the 
NOESY experiment carried out in H2O (red). 
 
Because complete resonance assignment could not be achieved using solely 
homonuclear data, 15N hMBD1 CXXC1 was prepared and 3D HSQC-TOCSY & HSQC-
NOESY was recorded 
 
4.3.3 Assignment using 3D spectra 
Assignment of cross peaks in 2D spectra is a very labour intensive process.  Any one 
horizontal or vertical at a particular chemical shift can have cross peaks belonging to 
more than one amino acid as figure 4.3 shows. By moving through the nitrogen 
dimension in 3D HSQC-TOCSY & HSQC-NOESY spectra we can distinguish spin 
systems based on their nitrogen chemical shift.  For example, R169 and R173 that have 
very similar HN chemical shift, their spin systems could be more completely assigned 
δ 1H 
(ppm) 
 
δ 1H (ppm) 
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using 3D HSQC-TOCSY & HSQC-NOESY since they have different nitrogen chemical 
shifts (figure 4.5).  
 
 
Figure 4.5 15N HSQC of hMBD1 CXXC1 showing different nitrogen chemical shifts 
for R169 and R173 
 
Not only do isotopically labeled samples allow the use of 3D experiments to help resolve 
overlapped regions but it also allows the use of analysis’s (Vranken et al, 2005) semi 
automated linking of spin systems.  When assigning cross peaks to a particular amino 
acid or spin system we look for specific correlations in the NOESY spectrum to help 
qualify the assignments e.g. HN to Hα NOE cross peaks for i to i+1, NOE cross peaks 
between sidechain and HN for i to i+1.  The software can automatically look for possible 
matches.  For example, starting from C176 (figure 4.6), analysis will look for NOE cross 
peaks assigned to the HN of other spin systems which match the chemical shifts of the 
assigned C176 TOCSY cross peaks.  As the residue following C176 is G177 we can 
look for cross peaks at a particular chemical shift amongst the matching spin systems.  
For a glycine we would expect to see 2 TOCSY cross peaks correlating both Hα protons 
to the HN proton. Once the next amino acid is identified the software can then be used to 
search for the next spin system to match to it.   
 
 
δ
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δ
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Assignment of H-H cross peaks in the HSQC-TOCSY spectrum allows the assignment 
of the N-H cross peak in the 15N-HSQC.  The complete assignment of the hMBD1 
CXXC1 15N-HSQC is shown in figure 4.7 which shows well dispersed peaks for most 
amides as well as nitrogen bound proteins in the side chains of glutamines 168, 183, 197 
and arginines 213 & 214.  Amino acids G162, M170, and H200 are unassigned in the 
HSQC.  Although there are still overlapped peaks in the 8.25ppm 1H region there is 
sufficient dispersion in the 15N chemical shift around 120ppm to resolve the cross 
peaks.  Also present are cross peaks which can be assigned to a minor form of the 
protein.  The minor form of the protein may be due to proteolysis, loss of a zinc ion or 
an incorrectly folded version.  Although there are N-H correlations from the minor form 
there are no visible cross peaks in the 15N-HSQC-TOCSY or 15N-HSQC-NOESY 
spectra.  
 
Using NMR experiments listed in table 3.1 (p75) a near complete assignment of hMBD1 
CXXC1 was possible.  Resonances that could not be assigned to cross peaks are listed in 
table 4.1.  These amino acids are found in unstructured regions of the hMBD1 CXXC1 
domain.   
 
Amino acids Unassigned protons 
R 169 Nε Hε 
F 171 γ 
R 173 Nε Hε 
H 200 Nδ1 Nδ2 
R 212 Nε Hε 
R 214 Nε Hε 
R 221 Nε Hε 
 
Table 4.1 list of protons and their amino acids that could not be assigned 
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δ
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Figure 4.6 Strips from 3D NOESY (blue) & TOCSY (green) spectra showing 
sequential assignment of amino acids C176 to C179 in hMBD1 CXXC1.  The dashed 
line shows the sequential links involving Hα, while the red arrows links NOE cross 
peaks correlating C176 Hβb to G176 HN and G177 HN 
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4.4 Structure calculation of hMBD1 CXXC1 using ARIA 
Since the majority of restraints for NMR structure calculations are provided by NOESY 
derived distance restraints, the cross peaks within the spectrum have to be assigned to a 
particular resonance.  However, due to the large population of protons within a protein 
many protons may share the same chemical shift so there may be several assignment 
possibilities for each NOE cross peak.  Manual assignment is a time consuming process 
which may not provide an accurate structure due to mis-assignment.  In order to speed 
up the process and reduce the risk of mis-assignment, structure calculations were carried 
out using the program ARIA 2.2 (Ambiguous Restraints for Iterative Assignment) 
(Rieping et al, 2007).  ARIA does not perform the structure calculations itself but drives 
the calculation of structures through the use of ambiguous distance restraints 
(unassigned crosspeaks which may have more than one contributing resonance) in an 
iterative structure calculation scheme.   Structures are calculated using the program CNS 
(Crystallography & NMR System) (Brunger et al, 1998), ARIA then analyzes the 
conformers obtained in order to update the restraints and obtain a set of improved 
conformers.  During distance restraint generation, non-degenerate prochiral chemical 
shifts e.g. methylene protons or the methyl groups of valine & leucine are arbitrarily 
stereospecifically assigned.  This can result in errors if the wrong member of a prochiral 
pair is chosen for a particular restraint.  To work around this, ARIA applies a floating 
chiral assignment testing both alternatives during structure calculation.  The 
conformation with the lowest energy is accepted for each prochiral centre.     
 
Distance restraints derived from NOESY cross peaks can be generated in two ways: 
restraints can be generated by ARIA itself or restraints can be generated in Analysis and 
imported into ARIA.  Both methods were tried for structure calculations as ARIA cannot 
use spin diffusion correction with restraints generated in Analysis. 
 
4.4.1 Structure calculation using constraints generated by Analysis 
Ambiguous distance constraints were generated in Analysis using the shift match 
restraint function.  This function generates a constraint list based on user defined input 
data.  Since the structure of the hMLL CXXC (Allen et al, 2006) domain was known it 
was hypothesized that certain secondary structures present would also be seen within the 
structure of the hMBD1 CXXC1 domain.  Amino acids 1170-1173 of hMLL CXXC 
form an alpha helix incorporating two cysteines from the second CXXCXXC cluster.  
Since the corresponding residues in hMBD1 CXXC1, 187-190, had strong NHi to NHi+1 
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and weak NHi to Hαi+1 NOESY resonances suggesting it was likely to be an alpha helix.   
Since the average distance of N-H1i to N-Hi+1 in an alpha helix is 2.8Å, the average NOE 
intensity of N-Hi to N-Hi+1 cross peaks for amino acids 191-195 should approximately 
correspond to a distance of 2.8Å.  Reference NOE intensities for two 2D NOESY and 
one 3D HSQC-NOESY experiments were calculated.  Parameters used for generating 
constraints are set out in Table 4.2.  To calculate the distance constraints for 
unambiguous cross peaks the same parameters were used. 
 
Ref. Distance 2.8Å   
Distance function Intensity^ –1/6   
Intensity type Height   
Max ppm tolerance F1 0.05 F2 0.05 F3 0.4 
Min ppm tolerance F1 0.05 F2 0.05 F3 0.4 
 
Table 4.2 Parameters used for generating distance constraints using CcpNMR.   
Analysis software.  F1 – direct proton dimension, F2 – indirect proton dimension, F3 – 
Nitrogen Dimension 
 
The problem with this method of distant constraint generation is that it is not currently 
possible to subsequently use ARIA’s spin diffusion correction algorithms to recalibrate 
the restraints based on the calculated structure.  For structures calculated from these 
restraints NOE energies failed to dip below 180 kJ mol-1 and it was not possible to obtain 
structures without violations below 0.5Å.  Persistent violations above 0.5 Å included 
intra-residue Valine HN to methyl groups and Histidine HN to β hydrogens.  Currently 
ARIA 2.2 does not support spin diffusion correction (chapter 4.4.4 p87) when importing 
distance constraints generated in Analysis.   
 
4.4.2 Structure calculation using constraints generated by ARIA 
In order to use spin diffusion correction during structure calculation, the assigned 
chemical shift list and crosspeaks were imported from Analysis into ARIA for each of 
the NOESY spectra.   The tolerances for direct, indirect proton and heteronuclear 
dimensions were set to 0.025, 0.025 and 0.25 respectively.  These values differ from the 
tolerances used in analysis due to the way they are used.  In Analysis the tolerance is the 
total distance across the crosspeak where as in ARIA the tolerance is set from the centre 
of the cross peak.  Therefore if the same tolerances used in Analysis for generating 
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constraint lists were to be used in ARIA, ARIA would produce significantly more 
constraints.  This would likely result in the generation of poor structure ensembles. 
 
Spin diffusion correction requires the input spectrometer frequency, mixing time and 
molecule correlation time into the ARIA project for each spectrum.  Molecule 
correlation time was worked out using stokes law.  The hydrodynamic radius was 
estimated from molecular weight.  
 
4.4.3 Additional restraints used by ARIA during structure calculations 
In addition to the distance restraint information generated from the NOESY spectra, 
restraints specifically for the co-ordination of each of the zinc ions by 4 cysteine residues 
were included during structure calculations.  In order to use zinc co-ordination restraint 
information, one of the cysteines involved in each cluster was defined as residue type 
CZN (cysteine + zinc ion) and the remaining 3 cysteines CYS in Analysis.  This 
involved the addition of residue definition files and changing the residues from CYS to 
either CZN or CYS of the protein sequence located in the molecule description.  To 
proceed with the calculation, the ARIA CNS protocol file was modified by the addition 
of a code patch.  This patch, provided by the ARIA programmers, defined the bond 
lengths between the sulfur atoms of the cysteines and the zinc ion as well as the bond 
angles (table 4.3).  Structure calculations without the zinc co-ordination restraints were 
also carried out to verify which cystines clustered together.       
 
Atoms Bond Length Bond Angle 
S  Zn 2.3 Å  
Cα – Cβ - S  114.3558 
Cβ - S - Zn  109.5000 
Hβ - Cβ - S  107.9185 
S – Zn - S  109.5000 
 
Table 4.3 Additional restraints used by ARIA for zinc co-ordination by four 
cysteine residues.  S, sulfur; Zn, zinc. 
 
Restraints generated from residual dipolar couplings, J couplings, dihedral angles, and 
disulphide bridges, can also be used during structure calculations by ARIA in order to 
build a more refined structure that can be produced by NOESY distance restraints alone. 
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4.4.4 Spin diffusion 
The choice of mixing time in a NOESY experiment is governed by a number of facts.  A 
NOESY experiment with a long mixing time has the advantage of no zero-quantum 
peaks (artifacts present in the NOESY spectra from J-coupled peaks, such as ortho-
protons on a ring).  Long mixing times allow for multiple magnetization transfers which 
distort cross peak intensity to distance relationship.  This multiple magnetization 
transfer, known as spin diffusion, can affect cross peaks between pairs of protons both 
close and far apart in space.  Protons close in space can be affected by back transfer of 
magnetization I1→ I2→ I1 reducing the intensity of NOE cross peak that would normally 
result.  Protons far apart in space can be affected by an indirect transfer of magnetization 
I1→ I2→ I3, increasing the intensity of the cross peak that would normally result or 
create a cross peak that would not normally exist in the absence of spin diffusion.  
Therefore, the mixing time needs to be long enough to let the NOE build up and allow 
zero-quantum effects to decay but short enough to minimise the chance of spin diffusion. 
As discussed in section 2.2.1 (p44) the NOESY experiment utilises dipolar interactions 
between two spins ≤5 Å apart.  The intensity of these cross peaks is used for calculating 
distance restraints.  If left uncorrected, spin diffusion leads to inaccurate distance 
restraints between protons leading to overly constrained and incorrect protein structures. 
Spin diffusion correction in ARIA (Linges et al, 2004) is based on the calculation of a 
theoretical transfer matrix from the set of structures produced in each iteration. The 
theoretical intensity values are then used to calibrate the experimental intensities and to 
correct the distance target. The calibrated intensities can be then used to estimate the 
error. 
 
4.4.5 Iterative structure calculation scheme 
ARIA uses an iterative strategy for structure calculations (table 4.4).  For the structure 
calculation of hMBD1 CXXC1, unambiguous (manually assigned resonances) and 
ambiguous restraints were used from the start, iteration 0.   When structures have been 
calculated, a user defined subset from the ensemble is chosen on the basis of their 
potential energy.  These structures are used to filter the restraints (partial assignment 
filter) based on their contribution to the intensity of the crosspeak.  Restraints which are 
above the threshold, a percentage of the total contribution, are removed from the 
restraint list.  Restraints that are not filtered out are used to recalibrate the spectra based 
on their average distance chosen from the subset of structures.  The restraint list is 
checked again for violations using the new intensity - distance matrix.  In the next 
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iteration structures are calculated based on the new restraint list created at the end of the 
previous iteration.  Each iteration subsequently reduces the partial assignment filter 
threshold and violation tolerance.  This process is repeated for a user defined number of 
iterations.  In order to improve the recalibration of restraints, spin diffusion correction 
was included from iteration 3 using a distance cut off of 6 Å.  The cut off is used to filter 
the calculated intensities used for correction, by including only those corresponding to a 
distance smaller than the distance cutoff value.  Assignment statistics are carried out on 
a user defined number of structures in each iteration which are selected on the basis of 
having lowest total energy.  The number of structures chosen to be used depends on the 
number of structures calculated in each iteration and the range of total energies of the 
ensemble.  The greater the number of structures calculated the greater number can be 
used for analysis.  In the initial round of structure calculations where assignment 
mistakes and artifact peaks are likely to be present there is no advantage in generating a 
large number of structures during each iteration.  Structure calculation can be a time 
consuming process depending on the number of processors that can be accessed.  With 
this in mind the total number of structures in each iteration generated in the initial round 
of structure calculations was set to 20.  
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Iteration 
Restraints 
Partial 
Assignment 
Filter 
Spin 
diffusion 
Violation 
Tolerance 
Å 
No. of 
Structures 
 
No of 
structures 
used for 
analysis 
0 
Original 
restraints 
1.0 No 10000 20 7 
1 
Checked 
restraints from 
round 0 
0.999 No 5.0 20 7 
2 
Checked 
restraints from 
round 1 
0.99 No 3.0 20 7 
3 
Checked 
restraints from 
round 2 
0.99 Yes 1.0 20 7 
4 
Checked 
restraints from 
round 3 
0.99 Yes 1.0 20 7 
5 
Checked 
restraints from 
round 4 
0.96 Yes 1.0 20 7 
6 
Checked 
restraints from 
round 5 
0.93 Yes 0.3 50 7 
7 
Checked 
restraints from 
round 6 
0.9 Yes 0.3 100 7 
8 
Checked 
restraints from 
round 7 
0.9 Yes 0.3 200 20 
 
Table 4.4 Iterative strategy used for hMBD1 CXXC1 structure calculation using 
ARIA.   
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For speed, structures are typically calculated “in vacuum” which can result artifacts as a 
result of the simplified treatment of non-bonded forces and missing solvent contacts.  
ARIA provides the option of refining structures in a shell of water molecules for a 
defined number of structures from the final iteration with a full molecular dynamics 
force field incorporating electrostatics (Linge et al, 2003).  This refinement helps to 
avoid unrealistic side chain packing and unsatisfied hydrogen bond donors or receptors.  
To ensure there are no systematic differences that could influence validation results, the 
force fields used for water refinement (file PARALLHDG 5.3) are consistent with the 
force fields used for structure calculation and validation.      
 
4.4.6 Analysis and report files 
At the end of each iteration, ARIA generates various output files which report the 
analysis ARIA carried out for each iteration. 
 
1. noe_restraints.unambig & noe_restraints.ambig:  These files contain all the 
unambiguous and ambiguous restraints, noting the reference cross peak, the 
restraint bound, the distance found in the ensemble and the result of the violation 
analysis 
2. noe_restraints.violations: lists just the violated restraints containing the same 
detail as for 1. above 
3. noe_restraints.assignments: provides information on wither the assignments 
stem from fully, partially or unassigned cross peaks. 
4. noe_restraists.merged: lists all restraints discarded by the merging procedure. 
5. report: summarises analysis of the restraint lists and the structure ensemble. 
 
In addition to these reports, ARIA can export the last iteration of structures (and water 
refined structures) to Analysis, a peak list of the assignments (for each spectrum) and a 
list of violated restraints which were not used for structure calculation in the final 
iteration.  Ambiguous assignment of resonances by ARIA is not infallible since noise 
and artifact peaks can be assigned if they match the chemical shift data.  ARIA can also 
mis-assign ambiguous peaks if any manual assignments are incorrect.  This is due to 
manual assignment forcing ARIA to satisfy the distant restraint calculated from the NOE 
crosspeak driving structure calculations in a specific way.  After each round of structure 
calculation violated peaks were inspected and either manually assigned or removed from 
the peak list.  Noise and artifact peaks are removed while mis-assigned peaks were 
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corrected.  Mis-assignment can be a problem if the tolerances for automatic assignment 
are set too low (see chapter 4.4.6) which can for example allow intra-residue cross peaks 
to be assigned as inter-residue.     
 
Once calculations started to yield structures that have low energies then the number of 
structures calculated in iteration 8 was increased.  An increase in the number of 
structures calculated will increase the number of low energy structures within the 
ensemble.  For example, if 20 structures are calculated they may not all be statistically 
similar even though they fit the experimental data.  However, if 200 structures are 
calculated, then 25 structures of the ensemble maybe of significant similarity.  Once 
NOE energies had reached a sufficiently low level, < 100 kJ mol-1, water refinement was 
introduced to the calculation.  Since the water refinement step introduces new 
constraints, the overall energies of the ensemble tend to increase.  Therefore there is no 
advantage in introducing this step in earlier round of calculations when the structures are 
not near converging.   When calculation produced structures of significantly low NOE 
energies <50 kJ mol-1 and no more improvement could be made using the current 
restraints, analysis was carried out to verify the precision and accuracy of the structures. 
Using NMR to generate a unique three dimensional structure is not possible because 
multiple structures can be calculated that are consistent with restraints derived from 
experimental data.  This is compounded by less defined regions of protein structure 
which are dynamic in solution.  Thus an ensemble of structures with the lowest energies 
can be produced to show a meaningful representation of the structure consistent with the 
experimental data. 
 
 
 
.   
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CHAPTER FIVE 
 
STRUCTURE AND FUNCTIONAL ANALYSIS OF HMBD1 CXXC1 
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5.1 Overview 
This chapter reports the structure of hMBD1 CXXC1 and discusses its implications in 
relation to the other known CXXC structures.  The CXXC domains that have been 
shown to bind non-methylated CpG contain a conserved amino acid sequence 
361KFGG364 and other conserved residues (D358 & Q370) as found in hMBD1 CXXC3.  
hMBD1 contains, depending on alternative splicing, 2 (55kDa) or 3 (66kDa) CXXC 
domains (Fujita et al, 1999, Jørgensen et al, 2004) with only the third CXXC domain 
capable of binding non-methylated CpG (Fujita et al, 2000 & Jorgensen et al, 2004).  
Recently, the solution structure of the MLL CXXC domain in complex with DNA 
(Cierpicki et al, 2009) and the crystal structure of DNMT1 CXXC (Song et al, 2010) 
have been solved revealing the amino acids responsible for DNA contact.  Comparison 
of these structures to hMBD1 CXXC1 reveals why hMBD1 CXXC is unable to bind 
non-methylated CpG.      
  
5.1.1 The solution structure of hMBD1 CXXC1 
The hMBD1 CXXC1 ensemble, comprising 20 lowest energy of 25 water refined 
structures (figure 5.1), shows a well defined backbone region for residues 173-196 & 
208-218, with the N- & C- termini and residues 197-207 poorly defined. RMSD was 
calculated for each residue using CcpNMR Analysis.  Analysis uses singular value 
decomposition (SVD) to calculate an optimum rotation for two coordinate sets with co-
located centroids. Each atom is weighted, both for the SVD and centroid calculation. 
There are multiple rounds of superimposition to get the ensemble from pairwise model 
comparison and to better refine the weights. Initially the weights come from the atomic 
masses, but in the later stages of the alignment the weights come from the atomic 
RMSDs calculated in the earlier round. Accordingly, the dissimilar parts have  
Proportionately little influence on the final ensemble. Figure 5.2 shows the per residue 
RMSD for the hMBD1 CXXC1 ensemble and the number of inter-residue NOEs from 
the 15N NOSEY.  Only the 15N NOSEY was used because the peak list imported from 
ARIA has less ambiguouity than the 2D 1H NOESY giving a truer representation of 
NOEs used.  Comparison of the number of inter-residue NOEs and RMSD of each 
residue reveal that the defined structured regions of the ensemble are characterized by a 
high number of inter-residue NOEs per residue while the N- and C- termini have very 
few inter-residue NOEs that consist mainly of short range, sequential correlations 
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Figure 5.1 A stereo view of the ensemble of 20 lowest energy of 25 final hMBD1 
CXXC1 solution structures superposed on the Cα of residues in well-defined regions 
(residues 175 to 196 & 208 to 217).  The less well defined loop (residues 197 to 207) is 
blue with the two cysteine clusters coloured red and green (Figure prepared using 
PyMol) 
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Figure 5.2  A. Per residue backbone and all atom RMSD for the final 25 hMBD1 
CXXC1 structures.  Red bars, backbone; black bars, all atom.  RMSD calculated using 
CcpNMR Analysis 2.1.5. B. Number of per residue NOE assignments from 15N-NOESY 
generated by ARIA for structure calculations in iteration 8.   
 
 
 
 
 
A 
B 
                                                                                                                                              99 
5.1.2 Precision of the ensemble of hMBD1 CXXC1 structures 
To be confidant that the ensemble of structures is an accurate representation of the 
experimental data the similarity of the structures was assessed by calculation of the Root 
Mean Squared Deviation (RMSD) of the atomic coordinates of each structure.  It is 
possible to calculate the RMSD by superposition on a selected structure (biased) or by 
global minimization of all fits (complete intensity).  However, by using an unbiased 
mean the calculation of the RMSD is not forced on one structure which may not be the 
most accurate representation of the ensemble.   To calculate the unbiased mean structure, 
the unweighted mean program UWMN (Hartshorn and Caves, University of York) was 
used.  UWMN creates a matrix containing the average distances between atoms in the 
ensemble of structures.  Since this matrix cannot typically be projected into cartesian 
space perfectly, the matrix is projected into multi-dimensional space and orientated so 
that when it is projected back into three dimensions the mean structure is calculated with 
the least loss of structural information.  The differences between the mean and the 
structures are listed as well as the average RMSD to the unbiased mean of the ensemble 
which is listed in table 5.1 
 
 
RMSD to the unbiased mean structure (Å) 
 
Heavy atoms 
 
1.143 
 
Backbone atoms 
 
0.854 
 
Table 5.1  RMSD of the final structures in the ensemble calculated to an unbiased 
mean.  RMSD calculated for residues 175-196 & 208-217.   
 
5.1.3 Geometric analysis of the ensemble of hMBD1 CXXC1 structures 
The geometric quality of an NMR structure can be validated by the distribution of the 
backbone (φ and ψ) side chain (χ1) torsion angles (Morris et al, 1992).  The φ angle is 
the dihedral angle between the HN and Cα, the ψ angle is the dihedral angle between the 
Cα and carboxylic carbon. The geometric quality of a structure can be analysed the 
program using Procheck-NMR (Laskowski et al, 1996).  Procheck-NMR assesses the 
stereochemical quality of structures by comparing them with the known stereochemical 
properties of well refined, high resolution X-ray structures.  Therefore, Procheck 
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assesses how normal, or how unusual, the geometry of the residues in a given protein 
structure is.  This analysis is reliant on the reference structures having normal geometric 
quality.  The summary of Ramachandran statistics for the residues (excluding all 
prolines and glycine residues) of the ensemble of hMBD1 CXXC1 structures is shown in 
table 5.2 and the plots shown in appendix B. Greater than 90% of the residues fall within 
most favorable and additionally allowed regions.  This is indicative of a structure with a 
good geometric quality.  The contribution of unfavorable φ and ψ angles (Appendix B, 
figure b2a-c) in the unstructured N- (163-174) & C- (217-222) termini as well as the 
poorly defined loop region (197-207) results in higher than average number of residues 
in the disallowed region.  This is due to a lack of restraints to define these regions of the 
domain.  If the unstructured regions are removed from the Ramachandran analysis, the 
percentage of residues in the disallowed regions is significantly reduced.      
 
Regions of Ramachandran plot  % residues 
       Residues in most favoured regions 61.3% (77.7%) 
       Residues in additional allowed regions 32.3% (21.0 %) 
       Residues in generously allowed regions 3.3% (0.7%) 
       Residues in disallowed regions 3.1% (0.7%) 
 
Table 5.2 Summary of the Ramachandran statistics for the ensemble of 25 hMBD1 
CXXC1 structures.  Percentage in brackets indicates statistics for well defined regions 
only (residues 175-196:208-216) 
 
 
The geometric quality of a structure can also be analysed by the distribution of side 
chain torsion angles χ1.  This is the angle of N-Cα-Cβ-Xγ1 about the Cα-Cβ bond.   The 
distribution of side chains in hMBD1 CXXC are relatively well defined with no residue 
lying in unfavourable regions (appendix B2d-e). 
 
Table 5.3 lists the statistics of experimental restraints used for calculating the structure 
of hMBD1 CXXC1.  Total number of NOEs represents NOEs merged from the three 
NOESY spectra.  The constraint violations and R.M.S deviation data refers to 20 lowest 
energy structures from 25 water refined structures calculated.   
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NMR Dist NMR distance restraints 
Total NOE 1327 
       Ambiguous (main contributors) 593 
             Intra-residue 204 
             Inter-residue 
 
                  Sequential (i-j=1) 156 
                  Short range (i-j= >1 <4) 118 
                  Long range (i-j>5) 115 
       Unambiguous 734 
             Intra-residue 334 
             Inter-residue 
 
                  Sequential (i-j=1) 211 
                  Short range (i-j= >1 <4) 102 
                  Long range (i-j>5) 87 
Constraint Violations per structure 
 
       >0.5 Å (+/- SD) 0.10 (+/- 0.06) 
       >0.3 Å (+/- SD) 1.35(+/- 0.16) 
       >0.1 Å (+/- SD) 19.05 (+/- 0.81) 
R.M.S. deviations from the ideal geometry 
 
       Bond length (Å)   0.0038 (+/- 0.000023) 
       Bond Angle (º) 0.600 (+/- 0.05) 
       Improper angles (º) 1.476 (+/- 0.04) 
       Dihedrals (º) 42.17 (+/- 0.137) 
 
Table 5.3 Experimental restraint statistics for hMBD1 CXXC1 
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5.2 Structural features of the hMBD1 CXXC1 zinc binding motifs 
The solution structure of MBD1 CXXC1 adopts a crescent shape incorporating two zinc 
ions (figure 5.3).  Four cysteines provide the ligands for the coordination of each zinc 
ion, three from each CXXCXXC motif.  The main chain loops back 180º after the 
second CXXCXXC motif to providing the fourth cysteine in each case.  The overall 
structure of the domain is governed by the presence of the two zinc clusters.  The zinc 
clusters have similar structures to each other with a backbone RMSD of 0.86 Å over the 
CXXCXXC sequence (calculated using Superpose. Maiti et al, 2004) and form a small 
helical turn between the first and second cysteines followed by a single turn of alpha 
helix, that includes residues 180A-183Q cluster 1 (figure 5.4a) and 192S-196L cluster 2 
(figure 5.4b).  However, the two CXXCXXC motifs appear to differ with respect to their 
side chain χ1 dihedral angles (Figure 5.3c).  This is consistent over the ensemble.  The χ1 
dihedral angles could be determined from J couplings determined from an HNHB 
experiment:     
 
 
 
 
Figure 5.3 A stereo view of the representative structure of the closest to the mean 
structure of the 25 calculated hMBD1 CXXC1 solution structures.  The zinc atoms are 
shown as gray spheres; alpha helix are shown in red and green; N, N-terminus; C, C-
terminus (Figure prepared using PyMol).  
 
N 
C 
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Figure 5.4 Stereo representation of the two cysteine zinc clusters from hMBD1 
CXXC1 (A) First CXXCXXC motif, residues 176-183 & 215  (B) Second CXXCXXC,  
motif residues 188-194 & 210  (C) superposition of the two CXXCXXC motifs. Sulphur 
atoms, yellow; zinc atoms, white (Figure prepared using PyMol). 
 
 
 
 
 
 
 
A 
B 
C 
188 
176 
215 
210 
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Figure 5.5 Stereo representation of the structural alignment of (A) hMBD1 CXXC1 
residues 176-183 & 215 (red) and hMLL CXXC residues 1155-1162 & 1194 (blue). (B) 
hMBD1 CXXC1 residues 188-194 & 210 (green) and the hMLL CXXC residues 1167-
1175 & 1189 (cyan).  White spheres, hMBD1 CXXC zinc atom; gray spheres, hMLL 
CXXC zinc atom. (Figure prepared using PyMol) 
 
The zinc clusters from hMBD1 CXXC1 have a fold which is very similar to the zinc 
clusters from hMLL CXXC (Figure 5.5).  Backbone RMSDs of 1.12 Å and 0.46 Å were 
calculated using Superpose (Maiti et al, 2004) for the first and second CXXCXXC 
motifs respectively.  A search of the structural data base http://www.ebi.ac.uk/pdbe-
site/pdbemotif/ for proteins that co-ordinate zinc by four cysteine residues revealed 62 
structures.  However, nine of these structures use two separated CXXC motifs to  
coordinate the zinc atom rather than the CXXCXXC motif found in hMBD1 CXXC1 
and MLL CXXC.  Alignment of the CXXC motifs found in the pdbe database to 
residues 179-182, 182-185, 188-191 and 191-194 hMBD1 CXXC1 reveals a highly 
similar backbone conformation with a pairwise RMSD 0.77 Å (±0.33).  Three structures 
A 
B 
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where found with a CXXCXXC motif: horse liver alcohol dehydrogenase (PDB - 1N8K) 
(Rubach & Plapp, 2003); E.coli RecQ helicase (PDB – 1OYW) (Bernstein et al, 2003) 
and the delta subunit of the clamp loader complex of E. coli DNA polymerase III (PDB 
– 1A5T) (Guenther et al, 1997).  The horse liver dehydrogenase has the fourth cysteine 
C-terminal to the CXXCXXC motif like hMBD1 CXXC1 and unlike the RecQ helicase 
and delta subunit of the clamp loader complex of E. coli DNA polymerase III in which it 
is N- terminal to the CXXCXXC motif.  Table 5.4 shows the pairwise RMSD for the 
CXXCXXC motifs of hMBD1 CXXC1 and the other CXXCXXC motifs described 
above.  Figure 5.7 shows the superposition of the CXXCXXC motifs from horse liver 
alcohol dehydrogenase, E.coli RecQ helicase, delta subunit of the clamp loader complex 
of E. coli DNA polymerase III and the second CXXCXXC motif from hMBD1 CXXC1  
 
 1N8K 97-103 1A5T 59-65 1OYW 397-403 
hMBD1 176-182 0.85 Å 0.98 Å 0.95 Å 
hMBD1 188-194 0.39 Å 0.49 Å 0.51 Å 
 
Table 5.4 Pairwise backbone RMSD of CXXCXXC motifs compared to the 
CXXCXXC motifs from hMBD1 CXXC1 domain. 1N8K, horse liver alcohol 
dehydrogenase; 1A5T, delta subunit of the clamp loader complex of E. coli DNA 
polymerase III; 1OYW, E.coli RecQ helicase. 
 
A common feature of all the CXXCXXC motifs of known structure is a glycine residue 
following the first cysteine.  Preference for glycine at this position may be due to the 
requirement for a positive phi angle following the first cysteine.  The CXXCXXC motif 
has a characteristic helical turn between the 1st and 2nd cysteines, similar to that of the 
single CXXC motif, before an alpha helix incorporating the 3rd cysteine (figure 5.6).  
Mutations of one of the zinc coordinating cysteines will destabilise the structure of the 
MLL CXXC domain (Allen et al, 2006. Cierpicki et al, 2009), MBD1 CXXC3 
(Stancheva et al, 2010) and CGBP (Skalnik et al, 2001) suggesting the CXXCXXC 
motifs are absolutely required for maintaining the structure of the domain. 
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Figure 5.7 Stereo view of the superposition of CXXCXXC motifs from hMBD1 
CXXC1 (red), horse liver dehydrogenase (black), E.coli RecQ helicase (blue), and the 
delta subunit of the clamp loader complex of E. coli DNA polymerase III (green).  
Cystine side chains shown as sticks, sulphur atoms in yellow.  
 
5.3 hMBD1 CXXC1 does not bind CpG DNA 
Previous DNA binding experiments (EMSA) have shown hMBD1 CXXC1 not to bind 
CpG DNA.  However, DNA titration by NMR would show weak binding that might not 
be observed by EMSA.  Although chemical shift perturbation analysis by 15N HSQC 
does not require the structure to be known, the assignment of spectrum crosspeaks is 
required to know which residues are affected by the titration of DNA.  When DNA is 
titrated into a protein sample a change in chemical shift will be recorded for any amino 
acid that is affected by the binding of the protein to DNA.  This change in chemical shift 
of a residue is due to an environmental change that may be due to direct interaction with 
the DNA or a resultant conformational change of the protein.     
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5.3.1 15N HSQC DNA titration of hMBD1 CXXC1 reveals no protein DNA 
interaction 
The titration of hMBD1 CXXC1 with DNA measured by 15N HSQC is shown in figure 
5.8.  There is little or no chemical shift perturbation with 3 fold excess DNA for the 
assigned resonances suggesting that hMBD1 CXXC1’s Kd for DNA is significantly 
above 150 µM.  However, small chemical shift perturbations are seen for the unassigned 
spin system 435 and the minor form A1203.  Resonance A1203 was assigned as the 
minor form of A203 as they share the same Hα and Hβ chemical shifts.  It is likely that 
resonance 435 is also from a minor form and since perturbation is only visible at the 3 
fold excess DNA concentration, this suggests non-specific DNA binding.  The minor 
form resonance A1203 is also only visible at the 3 fold excess DNA concentration.  This 
is likely due to unfolding or degradation of the protein during the course of the titration.  
Intensity differences are seen for glycine 165 and the side chain Nɛ of arginine 214.  
These highly solvent exchangeable resonances appear to be very sensitive to sample 
conditions since their intensities vary considerably from sample to sample.  It is 
therefore likely that the effect seen here is not  DNA-specific, but rather reflects small 
differences in ionic strength.  The lack of chemical shift perturbation that suggests no 
protein DNA interaction is consistent with the findings of Fujita et al (2000) and 
Jorgensen et al (2004) who observed no DNA shift in electrophoresis mobility shift 
assay experiments. 
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5.3.2 Why does hMBD1 CXXC1 not bind DNA? 
The MLL CXXC (Lee et al, 2001), MBD1 CXXC3 (Bird et al, 2004) , CGBP CXXC 
(Skalnik et al, 2001) and DNMT1 CXXC (Meehan et al, 2008., Pradhan et al, 2008.) 
have been shown to bind CpG DNA and therefore a comparison of the known DNA 
binding CXXC structures with that of hMBD1 CXXC1 should provide an insight as to 
why hMBD1 CXXC1 does not bind CpG DNA.  The solution structure of MLL CXXC 
(Cierpicki et al, 2008) and the X-ray crystal structure of DNMT1 CXXC (Song et al, 
2010) in complex with CpG containing DNA reveal that the positively charged face of 
the domain binds to the target DNA major groove.   
 
The MLL CXXC domain binds the CpG motif in the major groove though formation of 
hydrogen bonds to the CpG.  Using the terminology of Cierpicki et al (2009), the N4-
amine groups of the negative and positive stand cytosines hydrogen bond to the 
backbone oxygen of K1185 and K1186 respectively.  The side chain of K1186 forms 
hydrogen bonds to the negative strand guanine while the side chain amide of Q1187 
hydrogen bonds to positive strand guanine (Cierpicki et al, 2009).  Cierpicki et al (2009) 
also discovered weak NOEs between the side chains of R1150, S1152 and L1197 and 
the DNA minor groove and mutation of R1150 and L1197 to alanine resulted in a 5 and 
4 fold reduction in DNA binding affinity respectively.  DNA binding domains are 
generally evolved to contain positively charged amino acids though which they contact 
the negatively charged DNA phosphate backbone (Jones et al, 2003) while the shape of 
the DNA binding face is often complementary to the DNA duplex surface (Tsuchiya et 
al, 2004).   hMLL CXXC has made electrostatic interactions to the DNA and residues 
R1154, K1176, K1178, K1185, K1190, R1192, K1193.   
 
Table 5.5 show the corresponding residues from hMBD1 CXXC1 and xDNMT1 CXXC. 
hMBD1 CXXC1 differs from hMLL CXXC in many of the residues required for CpG 
DNA binding, not only in the residues that hydrogen bond to the CpG but also in 
residues involved in electrostatic interaction.  In addition to electrostatic interactions and 
hydrogen bonds, repulsive forces between the protein and DNA may reduce or 
ultimately abolish DNA binding.  Mutation of residue 1188 from a cysteine to an 
aspartate in hMLL CXXC is sufficient enough to abolish detectable DNA binding as 
mentioned by NMR.   
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hMLL CXXC hMBD1 CXXC1 xDNMT1 CXXC 
R1150 R161 E516 
S1152 A163 N518 
R1154 N165 I520 
K1176 Q197 M546 
K1178 P199 K548 
K1185 L206 T555 
K1186 F207 K556 
Q1187 C208 Q557 
K1190 E211 M560 
R1192 R213 R562 
K1193 R214 563 
L1197 I218 L567 
   
Table 5.5 List of residues involved in electrostatic interaction with DNA from 
hMLL CXXC1 (Cierpicki et al, 2009) and the corresponding residues in hMBD1 
CXXC1 and xDNMT1 CXXC. Residues mutated to alanine that abrogate DNA binding 
shown in bold, mutated residues that still bind DNA shown in blue.  
 
A surface charge plot of hMBD1 CXXC1 was produced using the Adaptive Poisson-
Boltzmann Solver (APBS) plugin in PyMol reveals a positive charge surrounding the 
first CXXCXXC motif while the second CXXCXXC motif and loop region has an 
overall negative charge.  This contrasts with the positive charged face of hMLL CXXC 
domain (figure 5.9).  In conclusion hMBD1 CXXC does not bind DNA because lacks 
the residues that are important for hydrogen bonding and has a slightly negative charged 
face compared to the strongly positively charged face of hMLL CXXC. 
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Figure 5.9 Stereo representation of the electrostatic surface potential of the hMBD1 
CXXC1 (A) and hMLL CXXC (B). Coloured using a linear colour ramp from -75.0 KT 
hMLL (red) to +75hMLL (blue).  (Figure prepared using the APBS plugin in PyMol) 
 
 
A 
B 
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5.4 Comparison of the loop region of hMBD1 CXXC1 and hMLL CXXC 
Currently the RCSB protein data bank contains three CXXC domain structures which 
are those of the hMLL CXXC domain (Allen et al, 2006., Cierpicki et al, 2008) and the 
DNMT1 CXXC (Song et al, 2010).  Figure 5.10 illustrates the structural superposition of 
hMBD1 CXXC1 with hMLL CXXC (PDB ID 2J2S) that has a pair wise RMSD of 1.83 
Å over the well defined regions of hMBD1 CXXC (residues 175-196 & 208-217).  The 
loop region residues 197-207 is not well defined in the  hMBD1 CXXC1 ensemble due 
to a lack of long range NOEs, whereas the loop region in hMLL CXXC is well defined 
in the NMR ensemble.     
  
 
 
Figure 5.10 Structural superposition of hMBD1 CXXC1 R169-S221 (blue) and 
hMLL CXXC S1152-W1196 (green), PKFGG loop (pink); red spheres hMBD1 CXXC 
zinc; black spheres hMLL CXXC zinc.  N, N-terminal; C, C-terminal (Figure prepared 
using PyMol) 
 
N 
C 
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A motif conserved in CpG DNA binding CXXC domains but not present in hMBD1 
CXXC1 (or hMBD1 CXXC2) is the KFGG motif (figure 5.11).  In hMBD1 CXXC1 the 
corresponding sequence is PHDV which has a significant effect on the structure of the 
loop region since compared with the phenylalanine the histidine is less hydrophobic and 
partially positively charged it is not able to be tightly packed into the main chain. The 
kink in the backbone (figure 5.12) due to the presence of a proline preceding the H200 
does not allow the hydrophobic side chain to pack up against β protons of cysteine 194, 
where as the proline in hMLL CXXC is two residues before the phenylalaine.   In 
DNMT1 CXXC the KFGG sequence is preceded by a lysine rather than the proline in 
the MLL CXXC domain.   
 
 
 
Figure 5.11 Comparison of second CXXCXXC motif & N-terminus of the loop 
region of hMBD1 CXXC1 C188 to V202 (A) and hMLL CXXC C1176 to G1181 (B) 
residues. N, N-terminal; C, C-terminal (Figure prepared using PyMol) QLPHD 
 
A B 
N N 
C 
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Figure 5.12 Stereo representation of the structural superposition of hMBD1 CXXC1 
C188-V202 and hMLL CXXC C1176-G1181. N, N-terminal; C, C-terminal (Figure 
prepared using PyMol) 
 
The solution structure ensemble of xDNMT1 CXXC (Thomson & Smith, unpublished) 
has a less well defined loop region than hMLL CXXC, therefore proline 1177 maybe 
required for loop stability.  Mutation of hMLL CXXC residues K1178 or F1179 to 
alanine significantly reduced the ability to bind a 12bp single CpG DNA in an EMSA 
(Allen et al, 2006).   These mutations of hMLL CXXC indicate that the precise, and 
ordered structure of this loop be required for efficient DNA binding. 
 
5.5 Conclusion 
The solution structure of hMBD1 CXXC1 presented in this thesis shows both 
similarities and differences to the known structures of hMLL CXXC (Allen et al, 2006) 
and DNMT1 CXXC (Song et al, 2010., Thomson & Smith, unpublished).  The two zinc 
coordinating cysteine clusters of the CXXCXXC domain form a common structure 
shared with both hMBD1 and DNMT1 CXXC.  This fold is highly likely to be common 
N 
C 
D201 
V198 
P199 
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to other CXXCXXC domains.   
However, hMBD1 CXXC1 lacks the KFGG motif which is present in the non-methyl 
CpG binding CXXCXXC domains.  The KFGG motif forms a small helix after the 
second CXXCXXC motif which appears to stabilise the DNA binding loop.  Mutations 
in this region have been shown to reduce DNA binding (Allen et al, 2006).  hMBD1 
CXXC1 also differs from other CXXCXXC domains by lacking residues important for 
DNA binding.  These differences not only change the surface charge of the loop thus not 
attracting the DNA through charge-charge interaction but lack the side chains to 
hydrogen bond to the DNA bases.  The function of hMBD1 CXXC1 is currently 
unknown although it has been shown to bind residues 250-337 of Ring1b (Min et al, 
2003).  Ring1b is a component of the Polycomb group (PcG) multiprotein PRC1 
complex (Min et al, 2003) which is required to maintain the transcriptionally repressive 
state of many genes.  Since hMBD1 CXXC3 does not interact with Ring1b that suggests 
the difference in the loop region of hMBD1 CXXC1 may be involved in the protein 
interaction with ring1b. 
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CHAPTER SIX 
 
NMR STUDY OF hMBD1 CXXC12 
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6.1 Overview 
The first two MBD1 CXXC domains lack the consensus sequence DXXKFGG and have 
been shown not to bind CpG DNA (Jorgensen et al. 2004).  The function of this pair of 
domains is still unknown although it has been shown to bind AA 250-337 of Ring1b 
(Sakamoto et al, 2007) suggesting a role in recruitment of the polycomb repressor 
complex 1 (PRC1) to DNA for maintenance of transcriptional repression.  hMBD1 
CXXC12 has also been shown to interact with the HMT SETDB1 and CAF150 in 
association with the MBD and TRD (Sarraf & Stancheva, 2004)  
 
With the structure of the first MBD1 CXXC domain known, I wish to ask wither the 
presence of the second MBD1 CXXC domain affects the 3D structure of hMBD1 
CXXC1?  Should the two CXXC domains interact, we would expect to see chemical 
shift perturbation for residues whose environment has been affected by the presence of 
the second CXXC domain.  Changes in the extreme C-terminal region of CXXC1 are 
also likely since this area should be more structured in the presence of CXXC2.   There 
may also be chemical shift changes for resonances assigned to the loop or well defined 
regions of CXXC1 if the CXXC2 domains interact more extensively.  
 
6.2 Cloning, expression of hMBD1 CXXC12 
Using the previously described pGEX 6P1 expression and purification system, PCR 
amplification of DNA containing the CXXC1 & CXXC2 of hMBD1 was performed 
using the primers shown in table 6.1.  The resultant fragment was cloned into pGEM T-
easy vector and subcloned into pGEX 6P1 as previously described in chapter 2.   The 
PCR (Figure 6.1), cloning into pGEM T-easy (Figure 6.2) and subcloning into pGEX 
6P1 (Figure 6.3) are shown below. Plasmids were sequenced to make sure no errors 
were present. 
 
 
hMBD1 CXXC1 fwd  5’ GGGATCCGAGCAGAGAATGTTTAAG 3’ 
hMBD1 CXXC2 rev 5’  CCTCGAGTTCAGCGGGCATGTTTA 3’ 
 
Table 6.1 Primers used for the PCR amplification of hMBD1 CXXC12.   
Restriction enzyme sites shown in bold & stop codon underlined. 
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The amino acid sequence of the expressed hMBD1 CXXC12 construct is shown in table 
6.2 which has a predicted molecular weight of 11.8 kDa.   Based on the structured region 
of hMBD1 CXXC1 it is likely the two domains are separated by a small linker sequence.   
 
 
GSEQRMFKRVGCGECAACQVTEDCGACSTCLLQLPHDVASGLFCKCERRRCL 
RIVERSRGCGVCRGCQTQEDCGHCPICLRPPRPGLRRQWKCVQRRCLRGKHAR 
 
 
Table 6.2 Amino acid sequence of the cloned hMBD1 CXXC12 domain.  The structured 
domain of CXXC1 is shown in red, the CXXC2 sequence shown in blue with the 
putative linker sequence underlined.    
 
                        
                             M                 1 
Figure 6.1 Agarose gel electrophoresis image hMBD1 CXXC12 PCR product. M – 
100bp DNA marker NEB (N3231), 1 – hMBD1 CXXC12 arrow indicated band of 
interest 
 
500bp 
400bp 
300bp 
                                                                                                                                              119 
500bp 
1 kb 
                            
Figure 6.2 Agarose gel electrophoresis of a selection of 2 putative pGEM-T hMBD1 
CXXC12 clones digested with BamH1 and Xho1. 1 - 1KB ladder NEB, 2 - 100bp ladder 
NEB, 3-4 putative pGEM-T hMBD1 CXXC12 clones.  Arrow indicates band of correct 
size for CXXC12 insert. Lane 4 show the expected fragment pattern 
 
                             
 
Figure 6.3  Agarose gel electrophoresis of a selection of 2 putative pGEX6P1-
hMBD1 CXXC12 clones digested with BamH1 and Xho1. The arrow indicates the 
expected position of the CXXC12 fragments. Clones 1 & 2 show the expected fragment 
pattern.  M- Bioline hyperladder 1 
 
 
   M            1              2 
        1         2       3         4 
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400 bp 
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6.3 Purification of hMBD1 CXXC12 
Purification of hMBD1 CXXC12 was carried out using the method described in chapter 
2.  Figure 6.4 illustrates the purification of hMBD1 CXXC12.  The preparation of 
hMBD1 CXXC12 was hampered by precipitation of the purified protein during 
overnight cleavage of the tag.   The protein sample suffered further precipitation during 
buffer exchange and concentration thus making it difficult to produce sufficient quantity 
for isotopic labeling in an economic way. 
 
                
                   1          2    3     4        5         6                7 
Figure 6.4  SDS-PAGE analysis of the expression and purification of hMBD1 
CXXC12 domain expressed in TunerTM DE3 cells. 1 – NEB prestained protein marker 
(cat. No. P7708S) , 2 – 5µl whole cell fraction, 3 – 5µl of soluble fraction, 4 – 5µl of 
flow through, 5 – 20µl of resin before Pre-Scission protease treatment, 6 – 20 µl resin 
after Pre-Scission protease treatment, 7– 20µl elution of hMBD1 CXXC12 domain.    
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17 
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6.4 NMR studies of hMBD1 CXXC12 
During long NMR experiments hMBD1 CXXC12 would degrade & precipitate.  This 
coupled with the lack of economic viability to express isotopically labelled protein 
meant that at this time it was only possible to record homonuclear experiments.  Shown 
in table 6.3 are the NMR experimental parameters for the 2D 1H NOSEY experiment7 
 
 
Table 6.3 Acquisition parameter of NMR experiment on hMBD1 CXXC12 (Bruker 
AVANCE 600 MHz) used for resonance assignment and structural restraints collection. 
Nuc: Nucleus, TD: time domain points (complex), SW: sweep width in Hz, RD: 
relaxation delay, NS: number of scans, WS: water suppression, ES: excitation sculpting, 
ms: milliseconds, 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  F1   F 2     
Experiment Nuc TD SW Nuc TD SW RDms NS WS 
100ms 
NOSEY 
1H 2048 8503 1H 1700 7001 1.0 32 ES 
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6.4.1 Is hMBD1 CXXC12 structured?  
To asses the quality of the CXXC12 sample, a 1D 1H experiment was carried out to 
investigate if the purified hMBD1 CXXC12 protein was structured.  The recorded 1D 1H 
spectrum of hMBD1 CXXC12 is shown in figure 6.5 
 
 
Figure 6.5 1D 1H spectrum of unlabeled hMBD1 CXXC12 (10mM dTris, 250mM 
NaCl, pH 7.5, 293K).  Water suppression using the method of Hwang and Shaka (1995) 
 
The 1D 1H spectrum of unlabeled hMBD1 CXXC12 suggests that the protein sample is 
folded due to the overall dispersion of chemical shifts and the 1H line widths.  The  
region of the spectrum around 10 ppm shows peaks clearly not present in the 1D 1H 
spectrum of CXXC1 while the peak around 0.5 ppm is still present.  Also the 6.5-8.5 
ppm region for CXXC12 is not as intense compared to the same region in CXXC1 
suggesting that fewer residues are in unstructured highly dynamic conformations.   
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6.4.2 Is CXXC1’s structure affected by the presence of CXXC2? 
A 2D homonuclear NOESY experiment was carried out in order to compare the 
spectrum with the 2D NOESY of hMBD1 CXXC1.  Figure 6.6 shows the Hα-HN region 
of hMBD1 CXXC12 & CXXC1 with the overlaid HN-HN region in figure 6.7.  Since the 
sample precipitated during the course of the experiment further 2D spectra that would 
present a more complete analysis could not be recorded. 
 
 
 
 
Figure 6.6  HN-Hα region of the 2D homonuclear spectra of hMBD1 CXXC1 (black) 
and hMBD1 CXXC12 (pink) overlaid (10mM dTris, 250mM NaCl, pH 7.5, 293K).  
Examples of assigned crosspeaks which have changed chemical shifts are indicated. 
 
δ 
1H (ppm) 
δ 
1H 
(ppm) 
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Figure 6.7 HN-HN region of the 2D homonuclear spectra of hMBD1 CXXC1 (black) 
and hMBD1 CXXC12 (pink) overlaid (10mM dTris, 250mM NaCl, pH 7.5, 293K).  
Examples of assigned crosspeaks which have changed chemical shifts are indicated.   
 
However, from a comparison of the CXXC12 & CXXC1 spectra it is clear that certain 
CXXC1 amino acids have altered chemical shift in CXXC12.  The most notable changes 
are seen in the dynamic loop region of CXXC1with amino acids S204 and P207, while 
others such as C179, A190 & T193 show no chemical shift change.  These chemical 
shift changes indicate a change in environment of the loop region suggesting that it is 
possibly in close proximity to the second CXXC domain.  In the loop region there are 
changes between the two constructs with the Hβ protons of C208 no longer correlated to 
the Hγ of T193 in CXXC12 while previously strong cross peaks have reduced intensity 
e.g. E211 γ protons correlation to C191 β protons.  These NOE changes in the loop 
region suggest the second CXXC domain is changing the shape of the loop region.  
Residues C179, A190, & T193 are found within the zinc clusters and seem to be 
unaffected by the presence of the second CXXC domain.  Residues at the extreme C-
terminus, amino acids 219-222, are unstructured when hMBD1 CXXC1 is expressed on 
δ 
1H (ppm) 
δ 
1H 
(ppm) 
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its own.  However, in hMBD1 CXXC12, their NOE cross peaks shift or disappear. 
Certain clearly identifiable crosspeaks in the CXXC1 2D NOESY such as the Hγ-HN of 
E220 and the sequential HN - HN & HN -Hα cross peaks for residues V219-R222 are 
absent or significantly shifted in the CXXC12 spectrum.  The lack of these NOE 
crosspeaks means that the structure of this region has changed in the CXXC12 construct.   
 
6.5 Conclusions 
Initial NMR experiments have shown that the expressed hMBD1 CXXC12 domains are 
structured in solution.  However, to carry out 3D NMR experiments to facilitate 
assignment and eventually structure calculations, protein purification conditions must be 
further optimized.  Changes to pH are limited with the use of PreScission protease due to 
a narrow functional pH range, but NaCl concentration can be adjusted up to 1 M.  
Therefore, it would be possible to significantly alter the salt concentration of the 
purification and NMR buffer in an attempt to prevent precipitation of the protein. 
 
Although the NOE data recorded is not sufficient to fully assign and calculate the 
structure of hMBD1 CXXC12, it is possible to suggest the relative orientation of the two 
CXXC domains.  There are significant NOE differences in the loop region (201N-209K) 
in hMBD1 CXXC12 to suggest there is a change in environment.  This may be due to 
the close proximity of the second CXXC domain.  In hMBD1 CXXC1 residues 216L-
222S are poorly constrained resulting in a flexible free end.  Therefore, it is unsurprising 
that there are chemical shift changed in this region since in hMBD1 CXXC12 they form 
a small interconnecting bridge between the two domains.  Due to the observed NOE 
changes it is likely that the two domains are folded together in one structure rather than 
two independent domains.  In order to verify this theory, recording 15N relaxation data 
for both constructs would provide information as to the relative dynamics of the two 
domains domain.  If the structure of CXXC12 was as suggested by the homonuclear 
NOE data then the 15N relaxation parameters recorded for each of the two domains 
would be quite similar and the T1/T2 ratios for CXXC12 should be indicative of an 
~12kDa globular species rather than independently tumbling ~6kDa species.  Should the 
precipitation problem with hMBD1 CXXC12 be overcome it will be possible to 
isotopically label the protein and carry out 3D NMR experiments.  It will also be 
possible to investigate the protein-protein interactions with amino acid 250-337 domain 
of ring1b (Sakamoto et al, 2007) with MBD1 CXXC12 once the domain is isotopically 
labelled.            
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Appendix A Laboratory buffers and methods 
 
Bacterial Growth Media 
Appropriate selection antibiotics were added in all media prior to use. 
 
LB Medium  1% (w/v) tryptone, 0.5% (w/v) yeast extract, 1% NaCl (w/v)  
5XM9 stock 3.4% (w/v) Na2HPO4, 1.5% KH2PO4, 0.25% (w/v) NaCl, 
autoclaved prior to use 
M9 minimal medium for 500 ml; 100 ml 5XM9, 2 mM MgSO4, 0.1 mM CaCl2, 0.3% D-
glucose (w/v), 8 mM (NH4)2SO4, 0.004% thiamine (w/v) 
Labelled medium For 15N labelling, replace 8 mM (NH4)2SO4 with 16 mM 15NH4Cl 
(Isotec, 11186AE).  
 
GST purification buffers 
Lysis/binding buffer  10× PBS: 1.4 M NaCl, 27 mM KCl, 100 mM Na2HPO4, 18 mM 
KH2PO4, pH 7.3.  Use at 1x 
PreScission buffer 50 mM  Tris-HCl (pH 8.0), 150 mM NaCl, 1 mM DTT 
Elution buffer  300 mM NaCl, 2.7 mM KCL, 10 mM Na2HPO4, 1.8mM KH2PO4, 
1 mM DTT, pH 7.3 
 
Bradford assay 
The protein concentration was measured using Bradford assay kit brought from Pierce 
(Product No. 23236). The measurement was performed according to the standard 
protocol in the manufacturer's instructions. 
 
SDS-PAGE 
Coomassie Stain 45% methanol, 45% dH2O, 10% acetic acid, 0.25% (w/v) 
coomassie R250  
Destain Buffer 5% methanol, 10% acetic acid, 85% dH2O  
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Appendix B Ramachandran plots, χ1torsion angle distributions and 
average secondary structure for the final ensemble of hMBD1 CXXC 
structures.  Structural analysis by Procheck-NMR 
 
Figure B.1 Graphical summary of Ramachandran statistics for the 
final ensemble of 25 hMBD1 CXXC structures. 
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Figure B.2 Per-residue Ramachandran plots for the final ensemble of 20 hMBD1 
CXXC1 structures.  Yellow boxes indicated favourable and red boxes indicate 
unfavorable φ, ψ dihedral angle combinations.  
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Figure B.2b Per-residue Ramachandran plots for the final ensemble of 20 
hMBD1 CXXC1 structures.  Yellow boxes indicate favourable and red boxes 
indicates unfavorable φ, ψ dihedral angle combinations respectively.  
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Figure B.2c Per-residue Ramachandran plots for the final ensemble of 20 
hMBD1 CXXC1 structures.  Yellow boxes indicate favourable and red boxes 
indicates unfavorable φ, ψ dihedral angle combinations respectively. 
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Figure B.2d Per-residue X1 frequency plots for the final ensemble of 20 hMBD1 
CXXC1 structures.  Yellow boxes indicated favorable and red boxes indicates 
unfavourable φ, ψ dihedral angle combinations.  
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Figure B.2e Per-residue X1 frequency plots for the final ensemble of 20 hMBD1 
CXXC1 structures.  Yellow boxes indicated favorable and red boxes indicates 
unfavourable φ, ψ dihedral angle combinations.  
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Figure B.2d Average secondary structure and accessibility plot for the final ensemble of 
25 hMBD1 CXXC1 structures  
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Appendix C Chemical shift assignments of hMBD1 CXXC1.  Chemical shifts are given in p.p.m, no chemical shift indicates unassigned or 
unobserved resonances 
Residue H N NE NZ NH HA HB HG HD HE HZ 
163Pro - - - - - 4.46 1.92,2.30 1.99,1.99 3.56,3.56   
164Leu 8.6 122.72 - - - 4.34 1.57,1.59 1.66 0.87,0.91 - - 
165Gly 8.56 110.52 - - - 3.95,4.05 - - - - - 
166Ser 8.24 123.15 - - - 4.35 3.82,3.89 - - - - 
167Glu 8.62 122.8 - - - 4.2 1.95,2.02 2.26,2.20 - - - 
168Gln 8.28 120.76 112.84 - - 4.2 1.96,2.07 2.34,2.34 - 7.59,6.90 - 
169Arg 8.24 121.54 - - - 4.21 1.73,1.73 1.51,1.57 3.14,3.14 - - 
170Met 8.19 - - - - 4.38 1.91,1.92 2.47,2.39 - - - 
171Phe 8.17 121.09 - - - 4.59 3.12,2.96 - 7.19 7.3 - 
172Lys 8.15 122.49 - - - 4.21 1.75,1.67 1.37,1.31 1.63,1.63 2.93,2.94 - 
173Arg 8.24 122.47 - - - 4.31 1.81,1.75 1.57,1.62 3.15,3.15 - - 
174Val 8.24 121.19 - - - 4.2 2.09 0.94,0.94 - - - 
175Gly 8.34 111.29 - - - 4.06,4.14 - - - - - 
176Cys 9.36 126.38 - - - 4.48 2.80,3.25 - - - - 
177Gly 9.55 115.33 - - - 3.83,4.35 - - - - - 
178Glu 9.62 123.72 - - - 4.57 1.93,2.06 2.15,2.22 - - - 
179Cys 7.12 120.34 - - - 4.7 2.98,3.46 - - - - 
180Ala 8.84 120.15 - - - 3.95 1.42 - - - - 
181Ala 7.39 120.51 - - - 4.4 1.28 - - - - 
182Cys 8.57 120.38 - - - 4.05 2.92,2.95 - - - - 
183Gln 7.44 114.45 111.92 - - 4.11 1.88,1.87 2.34,2.25 - 7.02,6.69 - 
184Val 7.21 122.55 - - - 3.92 2.25 1.19,1.02 - - - 
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Appendix C Chemical shift assignments of hMBD1 CXXC1.  Chemical shifts are given in p.p.m, no chemical shift indicates unassigned or 
unobserved resonances 
Residue H N NE NZ NH HA HB HG HD HE HZ 
185Thr 8.57 116.22 - - - 4.37 4.42 1.19 - - - 
186Glu 7.1 119.02 - - - 4.6 1.96,1.77 1.99,2.16 - - - 
187Asp 8.78 124.9 - - - 4.5 2.42,3.47 - - - - 
188Cys 9.39 127.21 - - - 4.47 3.29,2.84 - - - - 
189Gly 9.52 115.74 - - - 4.19,3.89 - - - - - 
190Ala 9.95 127.56 - - - 4.61 1.35 - - - - 
191Cys 7.06 119.33 - - - 4.85 3.40,2.97 - - - - 
192Ser 9.01 114.78 - - - 4.81 3.99,4.03 - - - - 
193Thr 7.89 117.58 - - - 4.01 4.26 1.04 - - - 
194Cys 9.01 126.91 - - - 3.96 2.98,2.92 - - - - 
195Leu 8.03 116.75 - - - 4.08 1.63,1.62 1.46 0.70,0.80 - - 
196Leu 7.42 119.34 - - - 4.17 1.87,1.87 1.5 0.84,0.92 - - 
197Gln 7.92 117.57 112.73 - - 4.15 2.08,2.02 2.31,2.32 - 6.86,7.53 - 
198Leu 8.32 122.95 - - - 4.52 1.60,1.41 1.64 0.90,0.91 - - 
199Pro - - - - - 4.39 1.86,2.30 2.02,2.02 3.84,3.55 - - 
200His 8.45 - - - - 4.51 3.10,3.10 - 8.16 7.11 - 
201Asp 8.22 120.5 - - - 4.55 2.65,2.65 - - - - 
202Val 7.93 120.82 - - - 3.93 2.08 0.92,0.92 - - - 
203Ala 8.31 124.63 - - - 4.23 1.39 - - - - 
204Ser 7.98 113.35 - - - 4.32 3.89,3.86 - - - - 
205Gly 8.13 110.16 - - - 3.87,3.96 - - - - - 
206Leu 7.89 121.02 - - - 4.2 1.44,1.43 1.34 0.74,0.81 - 7.23 
207Phe 8.07 119.02 - - - 4.53 2.97,3.12 - 7.18 7.29 - 
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Appendix C Chemical shift assignments of hMBD1 CXXC1.  Chemical shifts are given in p.p.m, no chemical shift indicates unassigned or 
unobserved resonances 
 
Residue H N NE NZ NH HA HB HG HD HE HZ 
208Cys 8.13 120.23 - - - 4.38 2.71,2.78 - - - - 
209Lys 8.15 123.48 - - - 4.19 1.58,1.65 1.36,1.37 1.58,1.58 2.90,2.90 - 
210Cys 8.56 125.58 - - - 3.87 2.91,2.30 - - - - 
211Glu 9.31 112.13 - - - 3.8 2.27,2.10 2.48,2.70 - - - 
212Arg 9.09 119.51 - - - 4.35 2.06,2.11 1.83,1.83 3.29,3.24 - - 
213Arg 7.54 114.39 83.8 - - 4.66 1.42,2.38 1.91,1.29 3.11,3.11 6.83 - 
214Arg 6.77 120.46 84.52 - - 4.04 1.63,1.77 1.51,1.84 3.15,3.19 6.67 - 
215Cys 8.23 126.72 - - - 3.89 2.98,2.76 - - - - 
216Leu 9.08 110.46 - - - 4.31 1.78,1.84 2.11 0.98,1.15 - - 
217Arg 9.33 121.68 - - - 4.38 1.95,1.81 1.69,1.58 3.31,3.28 - - 
218Ile 7.54 121.04 - - - 4.15 1.85 1.12,1.50,0.85 0.82 - - 
219Val 8.17 124.39 - - - 4.1 2.02 0.89,0.90 - - - 
220Glu 8.47 124.99 - - - 4.29 1.92,2.01 2.20,2.25 - - - 
221Arg 8.35 122.82 - - - 4.39 1.75,1.88 1.62,1.62 3.17,3.17 - - 
222Ser 8.04 123.13 - - - 4.24 3.83,3.84 - - - 
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